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Abstract
The purpose of this study was to determine the ergogenic response to different
caffeine doses of 3 mg/kg and 6 mg/kg consumed by trained cyclists 1 hour prior to a 40
kilometer cycling time trial. It was hypothesized that there would not be a difference in
time trial performance following caffeine supplementation of a 3 mg/kg dose as
compared to a 6 mg/kg dose. Sixteen male subjects, age 18-40, were initially assessed
via a VO2max test on an indoor cycle trainer. Subjects then reported to the lab on 4
separate occasions following a 10 hour fast and a 24 hour period of abstinence from
caffeine, for a 40 kilometer time trial on an indoor cycle trainer. One hour before their
time trial, subjects were given either 3 mg/kg or 6 mg/kg of caffeine or a placebo in
capsule form, administered in double-blind fashion along with 22 ounces of a 6%
carbohydrate/electrolyte solution. The effects of the different treatments on 40 kilometer
time trial time, average power output, heart rate, rating of perceived exertion, VO2, and
respiratory exchange ratio were assessed using Repeated Measures Analysis of Variance
with treatment as a within-subjects factor. Caffeine significantly improved 40 kilometer
time trial performance with 3mg/kg (P=0.004, 72.7 ± 4.6 min) and 6mg/kg (P=0.001,
71.6 ± 4.7 min) compared to the placebo (74.1 ± 5.4 min). The 6mg/kg dose also resulted
in a trend (using Bonferroni correction) to a significantly (P=0.04) improved performance
compared to the 3mg/kg dose. Results suggest that both 3 mg/kg and 6 mg/kg doses
improve 40K time trial performance, but a dose-response effect may exist such that a 6
mg/kg dose is more effective than a 3 mg/kg dose.

vi

CHAPTER 1: INTRODUCTION
Research has definitively established caffeine as an ergogenic aid for endurance
performance (6,7,8,13,21,23,43,45,46,49,57,58,70,74,82,86,99,104). For example, a
recent review of 21 studies that measured the effects of caffeine on endurance
performance with a time trial component; reported the mean improvement in
performance with caffeine was 3.2% ± 4.3% (40).
Research suggests the optimal effective dose for caffeine supplementation may
be ~5-6 mg/kg (1,3,5,6,13,18,22,27,32,41,49,56,57,59,66,74,75,82, 95,100,105,107).
However, a recent review indicated that doses between 3 and 6 mg/kg have been
commonly demonstrated to enhance performance (40). Furthermore, a recent review by
Burke (14) suggests a lack of a dose-response effect, in terms of further enhanced
performance, with caffeine levels beyond ~3 mg/kg.
Prior studies have reported a dose-response effect for greater performance
with a higher dose, albeit with dosage amounts less than ~ 3 mg/kg. Using an exercise
protocol similar to ours, Kovacs et al (70), reported significant improvement (p<0.01) in
a cycling time trial with caffeine doses of ~2.1 mg/kg, ~3.2 mg/kg, and ~4.5 mg/kg
compared to a placebo. There was no difference in performance between the ~3.2 mg/kg
and ~4.5 mg/kg doses, however they both resulted in a significantly (p<0.01) better
performance than the ~2.1mg/kg dose. Similarly, Jenkins et al (61) compared 15 minutes
of maximal effort cycling performance using 1 mg/kg, 2 mg/kg, or 3 mg/kg doses. The 2
mg/kg dose statistically (p=0.02) improved performance compared to the placebo, the 3
mg/kg dose trended (p=0.077) to improved performance compared to the placebo and the
1 mg/kg dose did not improve (p>0.05) performance compared to the placebo. However
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there were no differences (p>0.05) in performance between the 2 mg/kg or 3 mg/kg trial.
Likewise, Cadarette et al. (15) reported a significant (p<0.05) improvement in time to
fatigue on a treadmill run at ~80% VO2max with a 4.4 mg/kg dose ,but not a 2.2 mg/kg
dose, compared to a placebo. Although the authors reported no statistical (p>0.05)
difference between time to exhaustion following the 4.4 mg/kg dose and the 2.2 mg/kg
dose, the 4.4 mg/kg dose did increase time to exhaustion by 5.6 minutes compared to the
2.2 mg/kg dose.
Although limited in number, studies that have compared dosage amounts greater
than ~3 mg/kg (13, 66, 70, 88, 46) do seem to indicate a lack of a dose-response effect.
For example, Passman et al (86) reported a significant (p<0.05) improvement in cycling
time to exhaustion at 80% Wmax with caffeine doses of 5,9, and 13 mg/kg compared to a
placebo, with no difference between treatments. Likewise, Kovacs et al (70), reported
significant improvement (p<0.01) in a cycling time trial with caffeine doses of ~3.2 and
~4.5 mg/kg compared to a placebo, with no differences between treatments. Finally,
Bruce et al (13) reported a significant (p<0.05) improvement in a 2000 ergometer rowing
time trial following ingestion of both 6 mg/kg and 9 mg/kg doses of caffeine compared to
a placebo, with no difference between treatments.
Not only do the above studies suggest a lack of a dose-response effect, two
studies (15,46) may indicate potential for negative effects with dosage amounts greater
than 6mg/kg. Graham and Spriet (46) did not report any statistical difference in a
treadmill run time to exhaustion at 85% VO2max following ingestion of 3 mg/kg, 6
mg/gk or 9 mg/kg doses. Yet only the 3 and 6 mg/kg doses resulted in a statistically
significant (p<0.05) increase in performance compared to the placebo. Likewise,
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Cadarette et al (15) reported no statistical difference between a 4.4 mg/kg or 8.8 mg/kg
dose on treadmill run time to fatigue at 80% VO2max yet only the 4.4 mg/kg dose
resulted in a statistically significant (p<0.05) increase in performance compared to the
placebo.
Thus it appears that if a dose-response effect exists; there may be a threshold
effect such that the optimal dosage is most likely between 3-6 mg/kg.
Logically, a lack of a dose-response effect with caffeine may allow athletes to
ingest lower doses of caffeine and avoid common side effects of caffeine use such as
dizziness, headaches, anxiety, and tremors (58,110); thereby improving performance.
These side-effects have been reported in studies using doses greater than or equal to 9
mg/kg (46, 86) In fact, Graham (42) notes that a caffeine dosage of approximately 5
mg/kg causes saturation of the hepatic CYP1A2 system, which is the primary enzyme
involved in caffeine metabolism and accounts for approximately 95% of caffeine
clearance (51,52,67,89). Thus larger doses (>6mg/kg) may produce increases in plasma
caffeine levels and concomitantly increase negative side-effects (42). Additionally,
studies (13,86) have also reported that dosage amounts greater than 6 mg/kg resulted in
individual subject urinary caffeine levels above the allowable doping limit (>12μg/ml) set
by the International Olympic Committee whereas dosage amounts ≤ 6 mg/kg have not
(13, 22,86).
The purpose of this present study was to compare the effect of caffeine doses of 3
mg/kg and 6 mg/kg in trained cyclists on 40 kilometer cycling performance
Our hypothesis was that there would be no difference in 40k time trial
performance following ingestion of a 3 mg/kg dosage as compared to a 6 mg/kg dose.

CHAPTER 2: LITERATURE REVIEW
Caffeine and endurance performance:
Research regarding the ergogenic effect of caffeine on endurance performance
(Table 3.1) strongly supports the potential for caffeine to improve performance (8,46).
However, according to Ganio et al (40), performance improvements in non-cycling
endurance activities with a time-trial component may be somewhat less (in terms of
percent improvement) compared to endurance cycling. O’Rourke et al (82), Bridge et al
(12), Bruce et al (13), and Anderson et al (1) all reported statistically significant
performance improvements (5k run, 8k run, 2000 meter row, and 2000 meter row,
respectively) less than 1.4% following caffeine supplementation which lends support to
the findings of Ganio et al (40). One study did report a 31% improvement in
performance following caffeine supplementation, but that study was a run to exhaustion
rather than a time trial (40). Nevertheless, even a 1% improvement in performance can
impact the outcome of time trial race. For example, O’Rourke et al (82) reported that a
1% performance improvement in well-trained runners equated to an 11 second
improvement over the course of a 5 kilometer race. Likewise, Bridge et al (12) reported
that a 1.2% improvement in trained runners equated to a 23.8 second improvement over
the course of an 8 kilometer race. Thus caffeine appears to be an effective ergogenic aid
for improving endurance performance.
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Table 3.1 Effects of caffeine on endurance performance
Publication

Subjects

Caffeine
Dose

Protocol

Improved
Performance

Key Results

Running
Wiles et al
(108)
1992

Trained runners (10
male)

3 grams of
coffee (150200 mg
caffeine +
350ml hot
water(1 hour
pre-exercise)

1100 meters
at 1km/hr
slower than
average
fastest
running speed
followed by
400 meter
finishing
burst

Yes
(compared to
placebo)

Caffeine
significantly
improved
speed of final
surge (23.5
km/h vs. 22.9
km/h)
(p<0.05)

Wiles et al
(108)
1992

Trained runners (18
male)

3 grams of
coffee (150200 mg
caffeine)
+350ml hot
water (1 hour
pre-exercise)

1500 meter
time trial (3
trials
performed
and the mean
value taken)

Yes
(compared to
placebo)

Caffeine
significantly
improved
time by 4.2
seconds
(p<0.05)

Graham et al
(43)
1998

Trained runners (8
male, 1 female)

A=placebo
B=4.45 mg/kg
capsule +
water
C=Regular
coffee (4.45
mg/kg)
D=Decaf
coffee (0
mg/kg)
E=Decaf
coffee (0
mg/kg) + 4.45
mg/kg
capsule

Treadmill run
to exhaustion
at ~85%
VO2max

Yes (In trial B
only
compared to
all other
trials)

Trial B
(caffeine
capsule only)
significantly
increased time
to exhaustion
by 7.5-10:00
minutes vs. all
other trials
(p<0.05) and
by 31%
compared to
placebo D

Bridge et al
(12)
2006

Trained distance
runners (8 male)

3mg/kg (1
hour preexercise)

8 kilometer
race against
other subjects
on synthetic
track

Yes
(compared to
placebo and
control trial)

Caffeine
significantly
improved
time
(p=0.002)

Beck et al (4)
2008

Untrained/moderately
trained (31 male)

201 total mg
(45:00 preexercise)

Running time
to exhaustion
at 85%
VO2peak

No (compared
to placebo)

Caffeine time
to exhaustion:
14.3 minutes
and placebo:
14.2 minutes.
(p>0.05)
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Table 3.1(Concluded) Effects of caffeine on endurance performance
Publication

Subjects

Caffeine Dose

Protocol

O’Rourke et al
(82)
2008

Well trained
runners (15, no
data given for
male/female).
Recreational
runners (15, no
data given for
male/female)

5 mg/kg (1
hour preexercise)

Well-trained
rowers (8
male)

Anderson et al
(1)
2000

Swimming
MacIntosh et al
(74) 1995

Rowing
Bruce et al (13)
2000

Key Results

5 Kilometer
running trial

Improved
Performance
Yes (in both
groups
compared to
placebo)

6 mg/kg or
9mg/kg (1 hour
pre-exercise)

2000 meter
ergometer row
time trial

Yes (both trials
compared to
placebo)

6 mg/kg and
9mg/kg
improved
performance by
mean 1.3%
(p=0.01) and
1% (p=0.03)
respectively vs.
placebo.

Well-trained
rowers (8
female)

6 mg/kg or
9mg/kg (90:00
pre-exercise)

2000 meter
ergometer row

Yes (for both
trials compared
to placebo)

6 mg/kg
(p=0.06) and 9
mg/kg
(p=0.005)
improved
performance by
mean 0.7% and
1.3%
respectively vs.
placebo

Trained
swimmers (7
male, 4 female)

6 mg/kg (2.5
hours preexercise)

1500 meter
race (freestyle
stroke)

Yes (compared
to placebo)

Caffeine
significantly
(p<0.05)
improved swim
time (20:58.8±
36.4) vs.
placebo
(21:21.8 ±
38.2)

Caffeine
significantly
improved
running
performance in
both groups
(p<0.01). Well
trained group
improved by
1% (1047 ± 69
sec vs. 1058 ±
68 sec) and
recreational
group
improved by
1.1% (1286 ±
86 sec vs. 1298
± 84 sec)

Note: VO2max=maximal oxygen consumption; VO2peak=maximal oxygen consumption for that specific
mode of exercise
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Caffeine and cycling performance:
The ergogenic effect of caffeine supplementation on cycling performance is well
documented in the literature (Table 3.2). Additionally, Ganio et al (40) performed a
review of 21 studies that measured the effects of caffeine on endurance performance with
a time trial component. The 21 studies amounted to a total of 33 actual exercise trials
broken into the following: 21 cycling, 6 running, 4 rowing, 1 swimming, and 1 crosscountry skiing. The authors reported the mean improvement in performance following
caffeine supplementation was greatest in the cycling trials (4.4 ± 5.0%) compared to
running (0.9 ± 0.7%), rowing (1.1 ± 0.3%), swimming (1.7%) and cross-country skiing
(1.1%); therefore suggesting caffeine potentially has a greater effect on cycling than any
other endurance sport. Research indicates the ergogenic effects of caffeine on cycling
performance predominately equate to increased work performed during a time trial
(16,24,57,61,70,75,107) or increased time to exhaustion
(5,6,27,49,55,85,99,100,104,105). However, the effect of caffeine supplementation on
power production during cycling is somewhat more equivocal
(1,32,50,66,70,95,107,111). Although only three (50,107,109) of the aforementioned
studies reported no statistically significant (p>0.05) effect on power production as a result
of caffeine supplementation; two of them (50,107) reported performance improvements
in peak power and mean power that could be considered practically significant. For
example, Walker et al (107) reported a trend to significance (p=0.09) for an increase in
mean power over the course of a 30:00 time trial with caffeine (282 ± 39W) compared to
the placebo (271 ± 42W). The argument could also be made that the increase in mean
power observed was a factor in the statistically improved (p=0.046) time trial
performance of ~ 1:00 following caffeine supplementation. Also, although Greer et al
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(50) did not report a statistical increase (p>0.05) in peak power or mean peak power
following a 30 second Wingate test. Caffeine did increase peak power (1098 ± 198W,
1049± 192 W) and mean peak power (802 ± 124W, 762± 104W) compared to the
placebo.
Table 3.2 Examining the effects of caffeine on cycling performance
Publication

Subjects

Caffeine Dose

Protocol

Improved
Performance

Key Results

Endurance
Cycling
Van Soren et
al (105)
1998

Recreationally
trained (6
male)

6mg/kg caffeine 1
hour pre-exercise
following 0,2,4 days
withdrawl

Time to
exhaustion
while cycling
at fixed power
output =8085%VO2max

Yes
(compared to
placebo)

Caffeine
significantly
increased time
to exhaustion
in all trials
(p<0.05)

Kovacs et al
(70)
1998

Trained
cyclists (15
male)

A=placebo (14 total
ml/kg fluid)
B=7%CHO
+electrolyte
solution(CES)+0caff
C=CES +~2.1mg/kg
D=CES +
~3.2mg/kg
E=CES +
~4.5mg/kg.
Consumed 8ml/kg
55:00 prior to test,
then 3 ml/kg at 20
and 40 minutes of
exercise

Time Trial to
complete set
amount of
work
J=0.75wmax
x 3,600

Yes (all
caffeine trials
C,D,E
compared to
placebo A)
Also Yes in
caffeine trials
D,E,
compared to
trials B and C

All caffeine
trials
significantly
increased
work output
(W) and
significantly
decreased TT
time to
completion
compared to
placebo
(p<0.01).
Also, Trial D
(58.9 ± 1.0
min, 308 ± 9
W) and Trial
E (58.9± 1.2
min, 309 ± 10
W)
significantly
better
(p<0.01) than
trial A (62.5 ±
1.3 min, 292 ±
10 W) trial B
(61.5 ± 1.1
min, 295 ± 9
W), and trial
C (60.4 ± 1.0
min, 299 ±
10W)
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Table 3.2 (Continued) Examining the effects of caffeine on cycling performance
Publication

Subjects

Caffeine Dose

Protocol

Improved
Performance
Yes in 10%
below AT
(compared to
placebo).
No in 10%
above AT
(compared to
placebo.

Key Results

Denadai et al
(27)
1998

Untrained (8
male)

5mg/kg
+150ml hot
water and
decaf coffee (1
hour preexercise)

Cycle to
exhaustion at
10% above AT
and cycle to
exhaustion at
10% below AT
(AT =workload
corresponding
to lactate
concentration
of 4mmol)

Bell et al
(7)
1998

Recreational
(12 male)

5 mg/kg + 250
ml water
(90:00 preexercise)

Cycle to
exhaustion at
85% VO2peak

Yes?
(compared to
placebo, but
not statistically
significant)

Caffeine did
increase time
to exhaustion
(14.4 ± 4.1
minutes) vs.
(12.6 ± 3.1)
(p>0.05)

Greer et al (49)
2000

Active (8 male)

6mg/kg (90:00
pre-exercise)

Cycle to
exhaustion at
work load
=~80%-85%
VO2max.

Yes (compared
to placebo)

Caffeine
significantly
improved time
to exhaustion
by 22%
(p<0.05)

Sungpil et al
(100)
2001

Health, Rugby
players (5
male)

5mk/kg + 250
ml water (1
hour preexercise)

45:00 cycling
at 60%
VO2max
followed by
time to
exhaustion at
80% VO2max

Yes (compared
to placebo)

Caffeine
significantly
increased time
to exhaustion
(~63:00 vs.
~59:00)
(p<0.05)

Caffeine
significantly
increased time
to exhaustion
(46.54 ± 8.05
minutes) vs.
(32.42 ± 14.81)
(p<0.05) in
10% below
AT. No
significant
difference for
caffeine (18.45
± 7.28) vs.
(19.17 ± 4.37)
for 10% above
AT
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Table 3.2 (Continued) Examining the effects of caffeine on cycling performance
Publication

Subjects

Caffeine Dose

Protocol

Improved
Performance
No.

Key Results

Jacobson et al
(60)
2001

Highly trained
cyclists and
triathletes (8
male)

A=0 mg/kg
+CHO
B=6 mg/kg
+CHO
C=0 mg/kg
+Fat
D=6 mg/g +Fat
(1 hour preexercise)

120 steady
state cycling at
70%VO2max
followed by
time trial
requiring
completion of
set amount of
work (7kg/kg)
as fast as
possible

Cox et al (22)
2002

Trained
cyclists and
triathletes (12
male)

A=6 mg/kg 1
hour preexercise
B=6x1mg/kg
doses every
20:00 of
exercise
C=Placebo
D=2x5ml/kg
Coca Cola
instead of
sports drink
(=1.3 mg/kg
caffeine
All trials
(except D)
provided sports
beverage
throughout trial
=2.1g/kg of
CHO

120 minutes
cycling at 70%
VO2peak
followed by
time to
completion TT
=7kj/kg

Yes (caffeine
trials A,B, & D
compared to
placebo)

Trial A
significantly
improved time
to completion
by 3.4% vs.
Trial C
(p=0.04) Trial
B&D
improved time
to completion
by 3.1% vs.
Trial C and
trended to
significance
(P=0.06)

Bell et al (6)
2002

Aerobically
active (15
male, 6 female)

5mg/kg (1, 3,
or 6 hours preexercise) All
trials
consumed
5mg/kg of
Gatorade 1
hour preexercise.

Cycle to
exhaustion at
80% VO2peak

Yes (all
caffeine trials
vs. placebo)

Caffeine
significantly
improved time
to exhaustion
(28.8 ± 8.6
minutes) vs.
(24.0 ± 6.5)
(p≤0.05)

Time to
complete the
time trial was
significantly
less (p<0.05)
with CHO
trials A & B
vs. fat trials C
&
D. However no
difference for
caffeine trial B
vs. A or
caffeine trial D
vs. C.
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Table 3.2 (Continued) Examining the effects of caffeine on cycling performance
Publication

Subjects

Caffeine
Dose
A=5 mg/kg
A.M. and 2.5
mg/kg P.M.
B=0 mg/kg
A.M. and 0
mg/kg P.M.
C=5 mg/kg
A.M. and 0
mg/kg P.M.
D=0 mg/kg
A.M. and 5
mg/kg P.M.
(all given 1 hr
pre-exercise
along with
5mg/kg
gatorade)

Protocol

Bell et al (5)
2003

Recreational
cyclists (9
male)

Conway et al
(18)
2003

Improved
Performance
Yes (all
caffeine trials
vs. placebo)

Key Results

Trained
cyclists and
triathletes(9
male)

A=6 mg/kg 1
hr preexercise
B=3 mg/kg 1
hr preexercise and 3
mg/kg 45:00
into exercise

90:00 cycling at
70% VO2max
followed by time
trial at 80%
VO2max.

Yes?
(compared to
placebo, but
not
statistically
significant)

Caffeine
improved TT
performance
(23.8 ± 2.8
minutes vs. 28.3
± 3.1) (p=0.080)

Hultson et al
(57)
2008

Trained
cyclists (10
male)

A=0 mg/kg
+6.4%
glucose
solution
B=5.3 mg/kg
+ glucose (5.5
ml/kg fluid at
start and 2.2
ml/kg every
15:00 during
steady state.)

105 min steady
state cycling at
62% VO2max
followed by time
trial requiring
completion of set
work
(J=0.75Wmax x
2700seconds)TT=
~45:00

Yes
(compared to
trial A and
placebo)

Caffeine
significantly
improved TT by
4.6% vs. trial A
and 9.0% vs.
placebo (p<0.05)

Jenkins et al
(61)
2008

Trained
cyclists (13
male)

1mg/kg, 2
mg/kg, or 3
mg/kg (1 hr
pre-exercise
and all with
450 ml water)

15:00 cycling at
80% VO2peak
followed by 4:00
active recovery,
followed by
maximal effort
cycling for 15:00

Yes (2mg/kg
and 3 mg/kg
vs. placebo).
No (1mg/kg
vs. placebo)

2 mg/kg caffeine
significantly
improved work
performed by 4%
(p=0.02) vs.
placebo. 3mg/kg
improved work
performed by 3%
vs. placebo
(p=0.077)

Cycling to
exhaustion at
80% VO2max
twice a day. A.M.
and P.M.
separated by 5
hours.

In the A.M. trials:
Caffeine
significantly
increased time to
exhaustion by
31.3 ± 18%
(p<0.05). In the
P.M. trials:
Caffeine trial A
and trial C
significantly
increased time to
exhaustion vs.
trial B (p<0.05).
Also trial D P.M.
trial(caffeine)
was significantly
better than trial D
A.M. trial
(placebo)(p<0.05)
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Table 3.2 (Continued) Examining the effects of caffeine on cycling performance
Publication

Subjects

Caffeine Dose

Protocol

Hogervorst et
al (55)
2008

Recreationally
endurance
trained cyclists
(24 male)

A=power bar +
0 mg/caff
B=power bar +
100 total mg
C=Placebo
(consumed
5:00 preexercise and
again at 55:00
& 115:00 of
exercise)

150 minutes
cycling at 60%
VO2max
followed by
5:00 rest and
then time to
exhaustion trial
at 75%
VO2max

Walker et al
(107)
2008

Endurance
trained cyclists
(9 male)

6 mg/kg + 200
ml pink
grapefruit juice
(1 hr preexercise)

McNaugthon et
al (75)
2008

Trained
cyclists (6
male)

Short
Term/High
Intensity
Williams et al
(109)
1988

Anselme et al.
(2)
1992

Improved
Performance
Yes (caffeine
trial B vs. trial
A and C)

Key Results

90:00 cycling
at 70%
VO2max
followed by a
time trial
requiring set
amount of
work to be
performed
=energy
expenditure of
30:00 cycling
at 70%
VO2max

Yes (compared
to placebo)

Caffeine
significantly
improved TT
time (27.1 ±
1.7 minutes) by
4% vs. placebo
(28.2 ± 1.9)
(p=0.046)
Caffeine also
improved mean
power output
(282 ± 39 W
vs. 271 ± 42
W) but not
significantly
(p=0.09)

6 mg/kg (1
hour preexercise)

60:00 minute
time trial in
which subjects
covered as
much distance
as possible

Yes (compared
to placebo)

Caffeine
significantly
(p<0.02)
improved
distance
covered (28.0±
1.3 km) vs.
placebo (26.4 ±
1.5 km)

9 male

7mg/kg (1 hour
pre-exercise)

15 second
maximal
cycling bout

No (compared
to placebo)

Caffeine had
no effect on
peak power
output (p>0.05)

Recreationally
active (10
male, 4 female)

250 total mg
(30:00 preexercise)

Maximal effort
6 second sprint
on cycle
ergometer

Yes (compared
to placebo)

Caffeine
significantly
(p<0.02)
increased
Wmax (964 ±
65.77W) vs.
placebo (903.7
± 52.62W)

Caffeine
significantly
improved time
to exhaustion
(~1700
seconds) vs.
trial A (~1300
sec) and trial C
(~800 sec)
(p<0.01).
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Table 3.2 (Continued) Examining the effects of caffeine on cycling performance
Publication

Subjects

Caffeine Dose

Protocol

Jackman et al
(59)
1996

Recreational or
athletic
endurance
athletes (3
female, 11
male)

6mg/kg (1 hour
pre-exercise)

2:00 cycling at
power output
=VO2max
followed by
6:00 rest.
Repeat
exercise/rest
again. Exercise
to exhaustion
at same power
output

Kang et al (66)
1998

Professional
cyclists (7) PE
students (7)

2.5 mg/kg or
5.0 mg/kg
(prior to
exercise)

30 second
Wingate Test

Improved
Performance
Yes (compared
to placebo)

Key Results

Yes for both
groups and
doses
(compared to
placebo)

Professional
cyclists:
Caffeine
significantly
(p<0.05)
increased peak
power
(2.5mg=969 ±
67 W,
5.0mg=947 ±
93 W) vs.
placebo (845 ±
120W) as well
as mean power
(2.5mg=819 ±
87W,
5.0mg=826 ±
92W ) vs.
placebo (715±
85W)
PE Students:
Caffeine
significantly
(p<0.05)
increased peak
power (2.5
mg=823 ±
45W,
5.0mg=837±
94W) vs.
placebo (784 ±
79) as well as
mean power
(2.5mg=660±
62W, 5.0
mg=676± 68
W) vs.
placebo(625 ±
79W)

Caffeine
significantly
improved time
to exhaustion
(4.93± 0.60
min vs. 4.12 ±
0.36 min)
(p≤0.05)
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Table 3.2 (Concluded) Examining the effects of caffeine on cycling performance
Publication

Subjects

Caffeine Dose

Protocol

Improved
Performance
Yes (compared
to placebo)

Key Results

Doherty et al
(32)
2004

Trained
cyclists (11
male)

5mg/kg
+200ml water
(60 min preexercise)

2:00 at predetermined max
power output
followed by
1:00 maximal
effort

Schneiker et al
(95)
2006

Team sport
athletes (10
male)

6mg/kg
+200ml water
(60 min preexercise).
Also given
total of 600 ml
water and 600
ml gatorade
throughout
trial

Two, 36:00,
halves broken
into 18x2:00
blocks of 4 sec
sprint, 100 sec
active recovery
(35%VO2peak),
20 sec passive
recovery. Also
2x per half a
series of 5
sprints (2 sec)
followed by 18
sec recovery
were
performed.
10:00 rest
separated each
half.

Yes (compared
to placebo)

Caffeine
significantly
improved work
performed during
each sprint
(p<0.05),total
amount of sprint
work per half
(p<0.05), peak
power in each
sprint per half
(p<0.01), and
mean peak power
per half (p<0.01)

Greer et al
(50)
2006

Recreationally
active (18
male)

5 mg/kg (1
hour preexercise)

30 second
Wingate test

Yes?(compared
to placebo, but
not statistically
significant)

Caffeine had no
statistical effect
on peak power or
mean peak power
(p>0.05), but still
improved peak
power
1098±198W vs.
1049 ±192W and
mean power
802±124W vs.
762± 104W
placebo.

Mean power
during 1:00
effort
significantly
higher in
caffeine(794±164
W vs. 750 ±163
W) (p=0.05)

Note: CHO=Carbohydrate; W=Watts; TT=Time Trial; VO2max=maximal oxygen consumption;
VO2peak=maximal oxygen consumption for that specific mode of exercise; AT=Anaerobic Threshold;
Km=Kilometer
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Mechanisms for improved performance:
Research regarding the mechanisms (Table 3.3) for improved performance
observed following caffeine supplementation has established the following possible
mechanisms: 1. Caffeine causes an increase in free fatty acid (FFA) oxidation and thus
results in glycogen sparing. 2. Caffeine acts as an adenosine receptor antagonist in the
central nervous system. 3. Caffeine affects neuromuscular function by increasing
intracellular Ca++ concentration via its effect on the sarcoplasmic recticulum
(16,32,35,40,45,50,54,65,80,92,106).
Early studies thought the mechanism for improved endurance performance
observed with caffeine supplementation to be a result of increased FFA oxidation and
glycogen sparing (21,36,58). However, FFA concentration may not provide conclusive
evidence of FFA flow and oxidation during exercise (44). For example, Tamopolsky et
al (103), Van soren et al (105), Sungpil et al (100), and Bruce et al (13) all reported
significantly elevated FFA concentrations following caffeine supplementation yet only
Sungpil et al (100) reported a concomitant decrease in respiratory exchange ratio (RER).
In addition, only one other study from Table 3.3 reported a significantly decreased RER
following caffeine supplementation (108) Considering numerous studies in Table 3.3
observed a significant performance effect following caffeine supplementation yet
observed no difference in RER, rate of CHO or fat oxidation, or muscle glycogen net
utilization it seems likely other mechanisms are primarily responsible for the ergogenic
benefits of caffeine (13,49,61,92,105,107). Furthermore improved performance has also
been observed in protocols that would not generally elicit glycogen depletion
(17,32,49,61,82,105) which also implies other mechanisms may be at work.
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One such mechanism may be caffeine’s effect on the central nervous system via
its role as an adenosine receptor antagonist (29,37,38,42,68,84,85,87,96). Adenosine
receptors are found in several isoforms (A1, A2, A26, and A3) throughout the nervous
system as well as the vascular endothelium, heart, liver, adipose tissue, and muscle
(30,38,91). Adenosine has several inhibitory effects in both the central and peripheral
nervous systems including limiting spontaneous and neurotransmitter-evoked firing of
cortical neurons (33,72, 87). Additionally, during moderate or high intensity exercise,
adenosine concentration increases and binds to adenosine receptors located on the
sensory nerve endings. The resulting action may be an increase in pain signaling
(77,81,94).
The antagonistic effects of caffeine are thought to extend to all the isoforms
except the A3 isoform (37,96). Because caffeine is able to cross the blood-brain barrier, a
large effect of caffeine is found through its antagonism of the adenosine receptors in the
brain and central nervous system (9,24,64). Thus caffeine has the ability to decrease pain
perception, and increase neuro-excitability, neurotransmitter release, and arousal
(24,63,77,78,81,94). This effect serves to reduce the perceptual response in subjects to
exercise thus allowing them to either exercise at a higher intensity or exercise longer at a
fixed work rate (31, 98). A recent meta-analysis of 21 studies found that rating of
perceived exertion (RPE) during exercise was decreased by 5.6% with caffeine compared
to a placebo (31). Several studies from Table 3.3 also reported a reduction in RPE
following caffeine supplementation (5,6,22,27,32,57). Perhaps more indicative of the
inhibitory effects of caffeine on adenosine receptors are the studies in which absolute
RPE recorded at the end of exercise was no different for caffeine or placebo, but the work
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performed was significantly greater following caffeine use (13,56,61,74,95,108). This
suggests the subjects in those studies may have had a reduced pain sensation or have been
able to recruit more motor units (31).
The effects of caffeine’s antagonism of adenosine receptors are also thought to
extend to an increase in neuro-excitability and motor neuron firing rates (50, 90)
Additionally, caffeine has also been purported to act on neuromuscular function by
facilitating an increase in calcium mobilization in the sacroplasmic recticulum
(11,25,39,69,73,76,101). An increase in neuro-excitability would seem to potentially
increase maximal voluntary contraction, peak twitch torque, and motor unit firing rates;
however three studies from Table 3.3 did not report an effect of caffeine on those
variables. (76, 102, 103). On the other hand, both Kalmar et al (65) and Del Coso et al
(26) reported a positive effect on maximal voluntary contraction (MVC) as well as
voluntary activation of motor units following caffeine supplementation. Interestingly,
Kalmar et al (65) did not find an increase in twitch amplitude during MVC despite a
significant increase in MVC following caffeine use. Thus leading the authors to
speculate the increase in neuro-excitability takes place supraspinally (65).
Research has demonstrated the ability of caffeine to directly potentiate calcium
release from the ryanodine receptor at the sacroplasmic recticulum in vitro (88). Both
Meyers et al (76) and Kalmar et al (65) reported a significant (p<0.05) increase in a 50%
MVC held to exhaustion following caffeine supplementation leading the authors to
speculate that caffeine had a ergogenic effect on calcium reuptake and availability in
skeletal muscle. Similarly, Tarnopolsky et al (102) reported a significant (p<0.05)
increase in force of contraction at 20Hz following caffeine use, but found no effect on
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force of contraction at 40Hz. The authors attributed their difference in findings to
research suggesting that low frequency electrical stimulation results in fatigue at the level
of calcium release from the sacroplasmic reticulum whereas high frequency electrical
stimulation fatigue occurs at the neuromuscular level (10,34); thereby suggesting a direct
effect of caffeine on skeletal muscle (102). Although these findings support a potential
ergogenic effect of caffeine at the level of the sarcoplasmic recticulum; research has also
demonstrated that the plasma caffeine levels required to elicit calcium release from the
sacroplasmic recticulum may be toxic to humans (38, 65). Thus it is unclear the exact
nature of caffeine’s effect on the sacroplasmic recticlum in humans.
Table 3.3 Examining the purported mechanisms for ergogenic benefits observed with caffeine
supplementation (All studies either observed a significant performance effect with caffeine (p<0.05) or
only reported metabolic data*)
Publication
Subjects
Caffeine
Protocol
Mechanism
Key Results
Dose
Observed
Increased FFA
oxidation/Glycogen
Sparing
Cycling
Van Soren et al
(105)
1998

Recreationally
trained (6
male)

6mg/kg (1
hour preexercise)
following
0,2,or 4 days
withdrawl
from caffeine

Cycle to
exhaustion at
work rate
=80%-85%
VO2max

No (compared
to placebo)

No difference
in RER in
caffeine vs.
placebo. FFA
concentration
significantly
increased
(p=0.04) in
caffeine trial
vs. placebo
following 4
day withdrawl
only, but had
no effect on
performance
vs. other two
caffeine trials.

Denadai et al (27)
1998

Untrained (8
male)

5 mg/kg +150
ml water and
decaf coffee(1
hour preexercise)

Cycling to
exhaustion at
10% below
Anaerobic
Threshold

No (compared
to placebo)

No difference
between FFA
levels at end
of exercise
(p>0.05)
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Table 3.3 (Continued) Examining the purported mechanisms for ergogenic benefits observed with caffeine
supplementation (All studies either observed a significant performance effect with caffeine (p<0.05) or
only reported metabolic data*)
Publication
Subjects
Caffeine Dose Protocol
Mechanism
Key Results
Observed
6 mg/kg +
90:00 treadmill No (compared
Despite a
Tarnopolsky et Trained
runners
(6
250ml
run
at
70%
to
placebo)
significant
al (102)*
male)
lemonade
(1
VO2max
increase in
2000
hour preFFA
exercise)
concentration
with caffeine
(p<0.05) at 0
and 60 minutes
of exercise; no
change in RER
was detected
Greer et al (49)
2000

Greer et al
(49)*
2000

Roy et al (92)*
2001

Active (8
male)

6mg/kg (1 hour
pre-exercise)

Cycling to
exhaustion at
workload=80%85% VO2max

No (compared
to placebo)

No difference
in RER (1.0 ±
0.02 caffeine
vs. 1.0 ± 0.03
placebo) or
serum FFA
concentration

Active (7
male)

6 mg/kg (1
hour preexercise)

45:00 cycling at
70% VO2max

No (compared
to placebo)

No difference
in muscle
glycogen net
utilization
(p>0.05)

Trained
cyclists (7
male, 5 female)

6 mg/kg (75:00
pre-exercise)

60:00 cycling at
65% VO2peak

No (compared
to placebo)

No significant
difference
(p>0.05)
between trials
for fat
oxidation,
CHO oxidation
or RER (0.90
± 0.04 placebo)
vs. (0.91 ±
0.03 caffeine).
No significant
difference in
serum FFA
concentration
although trend
(p=0.10) for
greater FFA
concentration
with caffeine
as exercise
continued
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Table 3.3 (Continued) Examining the purported mechanisms for ergogenic benefits observed with caffeine
supplementation (All studies either observed a significant performance effect with caffeine (p<0.05) or
only reported metabolic data*)
Publication
Subjects
Caffeine Dose Protocol
Mechanism
Key Results
Observed
Sungpil et al
Trained Rugby 5 mg/kg +
45:00 cycling
Yes (compared In the 45:00
(100)
athletes (5
250ml water (1 at 60%
to placebo
bout of
2001
male)
hour preVO2max
during the
cycling:
exercise)
followed by
45:00 trial)
caffeine
cycling to
significantly
exhaustion at
(p<0.05)
80% VO2max
increased fat
oxidation and
plasma FFA
concentration
and
significantly
(p<0.05)
decreased CHO
oxidation and
RER (0.83±
0.01 caffeine
vs. 0.85 ± 0.01
placebo)
Walker et al
(107)
2008

Trained
cyclists (9
male)

6 mg/kg +
250ml pink
grapefruit juice
(1 hour preexercise)

90:00 cycling
at 70%
VO2max
followed by
time trial
requiring
work=30:00
cycling at 70%
VO2max

No for both
90:00 bout of
cycling and the
time trial
(compared to
placebo)

Caffeine did
not have an
effect on CHO
or FAT
oxidation rates
during 90:00
cycling
(p>0.05) or on
FFA
concentration
post time trial
(p>0.05).

Jenkins et al
(61)
2008

Trained
cyclists (13
male)

1mg/kg, 2
mg/kg, or 3
mg/kg + 450
ml water (1
hour preexercise)

15:00 cycling
at 80%
VO2peak, 4:00
active
recovery, 15:00
maximal effort
cycling

No (compared
to placebo)

No significant
difference in
RER for either
15:00 bout of
cycling
(p>0.05) with
caffeine vs.
placebo

Running
Wiles et al
(108)
1992

Trained
runners (10
male)

3 grams coffee
(150-200 mg
caffeine) +
350ml water (1
hour preexercise)

1100 meter run
at speed 1
km/hr slower
than average
fastest running
speed followed
by 400 meter
finishing burst

Yes (compared
to placebo)

Mean RER
significantly
less with
caffeine (0.98)
vs. placebo
(0.99) (p<0.05)
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Table 3.3 (Continued) Examining the purported mechanisms for ergogenic benefits observed with caffeine
supplementation (All studies either observed a significant performance effect with caffeine (p<0.05) or
only reported metabolic data*)
Publication
Subjects
Caffeine Dose
Protocol
Mechanism
Key Results
Observed
Rowing
Bruce et al
Well-trained
6 mg/kg or 9
2000 meter
No? (compared Caffeine did
(13) 2000
rowers (8
mg/kg (1 hour
ergometer row to placebo)
significantly
male)
pre-exercise)
time trial
(p<0.05)
elevate FFA
concentration
throughout ,but
no significant
difference
(p>0.05) in
RER for 6mg
(1.05 ± 0.06)
9mg (1.02±
0.05) or
placebo (1.06
Influence on
± 0.09)
CNS activity
Cycling
Denadai et al
(27)
1998

Untrained (8
male)

5 mg/kg + 150
ml hot water and
decaf coffee (1
hour preexercise)

Cycle to
exhaustion at
10% below
anaerobic
threshold

Yes (compared
to placebo)

Caffeine
significantly
reduced RPE
(14.1 ± 2.5) vs.
placebo (16.6
± 2.4) at end of
exercise
(p<0.05)

Bell et al (6)
2002

Aerobically
active (15
male, 6
female)

5 mg/kg at 1
hour, 3 hours, or
6 hours preexercise +
5mg/kg gatorade
1 hour preexercise

Cycle to
exhaustion at
80% VO2peak

Yes (compared
to placebo)

Caffeine
significantly
lowered RPE
during cycling
to exhaustion
trial (p<0.05)

Cox et al (22)
2002

Trained
cyclists and
triathletes (12
male)

A=6 mg/kg 1
hour prior
exercise
B=6x1mg/kg
doses every
20:00 during
exercise
C=2x5ml/kg
coca cola
instead of sports
drink(=1.3mg/kg
caffeine)
D=Placebo

120 minutes
cycling at 70%
VO2peak
followed by
time trial
=7kj/kg. All
subjects
(except C)
given sports
drink during
trials equal to
2.1g/kg of
CHO over ~2.5
hour period

Yes (trial A
compared to
placebo during
exercise) and
Yes (Trial A,
B compared to
placebo at end
of 120 minutes
compared to
placebo)

Caffeine trial
A significantly
reduced RPE
(p<0.05)
during exercise
trial. Caffeine
trial A,B
significantly
reduced RPE
(p<0.05) at
finish of 120
minutes
exercise
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Table 3.3 (Continued) Examining the purported mechanisms for ergogenic benefits observed with caffeine
supplementation (All studies either observed a significant performance effect with caffeine (p<0.05) or
only reported metabolic data*)
Publication
Subjects
Caffeine Dose Protocol
Mechanism
Key Results
Observed
Bell et al (5)
Recreationally
A=5 mg/kg in
Cycle to
Yes (compared Caffeine
2003
trained cyclists A.M. & 2.5
exhaustion at
to placebo)
significantly
(9 male)
mg/kg P.M.
80% VO2max
lowered RPE
B=Placebo
in A.M. and
in A.M. trials
A.M. and P.M. P.M.
(p<0.05)
C=5 mg/kg in
(separated by 5
A.M. &
hours)
placebo P.M.
D=Placebo
A.M. & 5
mg/kg P.M.
with gatorade
=5mg/kg (1
hour preexercise)
Doherty et al
(32)
2004

Trained
cyclists (11
male)

5 mg/kg +
200ml water (1
hour preexercise)

2:00 cycling at
maximum
power output,
then 1:00
maximum
effort to cover
maximal
distance

Yes (compared
to placebo)

Caffeine
significantly
lowered RPE
(p<0.05)
during 2:00
cycling bout

Yeo et al
(111)*
2005

Trained (8
male)

A=0mg/kg +
0.3 g/min
glucose drink
B=5mg/kg +
glucose drink
C=Placebo (all
given as 150ml
fluid every
15:00 of
exercise)

3 different 120
minute bouts of
cycling at 55%
maximal power
output

No (compared
to placebo)

Caffeine had
no effect on
RPE (p<0.05)

Schneiker et al
(95) 2006

Team sport
athletes (10
male)

6 mg/kg
+200ml water
(1 hour preexercise) Also
given 600 ml
of both
gatorade and
water
throughout trial

Two 36:00
halves of
cycling with
10:00 rest
between. 18
x2:00 blocks
per half of 4
sec sprint, 100
sec active & 20
sec passive
recovery. Also
twice per half
:5 (2 sec)
sprints with 18
sec recovery

Yes?
(compared to
placebo)

Caffeine had
no effect on
absolute RPE
but caffeine
group
performed
significantly
more total
work and sprint
work per half
& peak power
per sprint per
half (p<0.05)

Table 3.3 (Continued) Examining the purported mechanisms for ergogenic benefits observed with caffeine
supplementation (All studies either observed a significant performance effect with caffeine (p<0.05) or
only reported metabolic data*)
Publication
Subjects
Caffeine Dose Protocol
Mechanism
Key Results
Observed
Hogervorst et
Endurance
A=0mg/kg +
150 minutes of
No (compared Caffeine had
al (55)
trained,
powerbar
cycling at 60%
to placebo)
no effect on
2008
recreational
B=100 mg
VO2max , 5:00
RPE (p>0.05)
cyclists (24
+powerbar
break, Time trial
during the 150
male)
C=Placebo
to exhaustion at
minutes of
consumed
75% VO2max
steady state
5:00 minutes
cycling
prior to & at
55:00&115:00
of exercise
Hulston et al
(57)
2008

Trained
cyclists (10
male)

A=0mg/kg +
6.4% glucose
solution
B=5.3mg/kg
+glucose
(consumed as
5.5 ml/kg fluid
every 15:00
during steady
state)

105 minutes
steady state
cycling at 62%
VO2max
followed by time
trial with work
=0.75Wmacx2700
seconds

Yes
(compared to
Trial A and
placebo)

Caffeine (B)
significantly
reduced RPE
during steady
state (10.9 ±
0.2) vs.
placebo (12.0
± 0.3) & trial
A (11.8 ± 0.2)
(p<0.05)

Jenkins et al
(61)
2008

Trained
cyclists (13
male)

1 mg/kg, 2
mg/kg, or 3
mg/kg +
450ml water
(1 hour preexercise)

15:00 cycling at
80% VO2peak,
4:00 active
recovery, 15:00
maximum effort
cycling

Yes?
(compared to
placebo)

Caffeine had
no effect on
absolute RPE
but 2 and 3
mg/kg groups
performed 4%
(p=0.02) and
3% (p=0.077)
more work vs.
placebo
respectively.

Running
Wiles et al
(108)*
1992

Trained
runners (6
male)

3 grams coffee
(150-200 mg
caffeine) 1
hour preexercise

1500 meter
treadmill run at
0.5 km/hr slower
than average
speed of fastest
recorded 1500
meter treadmill
run

No (compared
to placebo)

Caffeine had
no effect on
absolute RPE,
but resulted in
significantly
faster speed of
final surge
(p<0.05)

Trained
distance
runners (8
male)

3 mg/kg (1
hour preexercise)

8 kilometer race
against other
subjects on
synthetic track

Yes?
(compared to
placebo)

Caffeine had
no effect on
absolute RPE,
but
significantly
improved
performance
(p=0.002)

Bridge et al
(12)
2006
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Table 3.3 (Continued) Examining the purported mechanisms for ergogenic benefits observed with caffeine
supplementation (All studies either observed a significant performance effect with caffeine (p<0.05) or
only reported metabolic data*)
Publication
Subjects
Caffeine Dose Protocol
Mechanism
Key Results
Observed
Repeated
Team sport
5 mg/kg (1
12 x 30 meter
No (compared
Caffeine had
Sprints
Glaister et al
athletes (21
hour presprints
to placebo)
no effect on
(41)
male)
exercise)
repeated at 35
RPE
2008
second
intervals
Well-trained
rowers (8
male)

6 mg/kg or
9mg/kg ( 1
hour preexercise)

2000 meter
ergometer row
time trial

Yes?
(compared to
placebo)

Caffeine had
no effect on
absolute RPE
but resulted in
significantly
enhanced
performance
(p<0.05) vs.
placebo

Trained
swimmers (7
male, 4
female)

6 mg/kg (2.5
hours preexercise)

Yes?
(compared to
placebo)

Yes?
(compared to
placebo)

Resistance
Exercise
Hudson et al
(56)
2008

Caffeine had
no effect on
absolute RPE,
but resulted in
significantly
faster swim
time (p<0.05)

Moderately
trained (15
male)

6 mg/kg +
500ml water (1
hour preexercise)

Leg extensions
to failure at
weight =12
repetition
maximum for
4 sets with
3:00 rest
between sets

Yes?
(compared to
placebo)

Neuromuscular
Function
Tarnopolsky et
al (103)
1989

Caffeine had
no effect on
absolute RPE,
but caffeine
group
performed
significantly
more
repetitions
(p<0.05)

Varsity level
runners (6
male)

6 mg/kg +
250ml
lemonade (1
hour preexercise)

Evoked Peak
Twitch Torque
(PTT) and
Maximal
Voluntary
Contraction
(MVC)
measured
pre/post 90:00
treadmill run at
70% VO2max

No(compared
to placebo)

Caffeine had
no effect on
PTT or MVC
isometric
torque
(p>0.05)

Rowing
Bruce et al (13)
2000

Swimming
MacIntosh et al
(74)
1995
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Table 3.3(Continued) Examining the purported mechanisms for ergogenic benefits observed with caffeine
supplementation (All studies either observed a significant performance effect with caffeine (p<0.05) or
only reported metabolic data*)
Publication
Subjects
Caffeine Dose Protocol
Mechanism
Key Results
Observed
Kalmar et al
11 Male
6 mg/kg (1
Pre/Post Test
Yes from preCaffeine
(65)
hour before
separated by 1
to-post
significantly
1999
post-test , but
hour: H-reflex
test(compared
increased MVC
right after prestimulation of
to placebo for
torque pre-totest)
the Soleus
MVC torque,
post test
muscle. MVC
Surface EMG
(p<0.05), while
of quadriceps
during MVC,
it decreased
muscle +
Voluntary
with placebo.
superimposed
activation of
Caffeine
twitches during motor units
increased
which maximal and MVC to
surface EMG
EMG also
fatigue)
during MVC
recorded. 10
No from prepre-to-post test
second
post
while placebo
submaximal
test(compared
decreased but
contractions of to placebo for
no significant
quadriceps at
twitch
difference in
25%, 50%, and amplitude
changes.
75% MVC
during MVC,
Caffeine
with 90 second Average motor significantly
rest during
unit firing rates increased
which surface
during
Voluntary
EMG and
submaximal
activation of
single motorcontractions,
motor units
unit firing rates Surface EMG
pre-to-post test
were recorded. during
(p<0.01) while
One 50% MVC submaximal
it decreased
isometric
contractions,
with placebo.
contraction of
and Alpha
Caffeine
quadriceps to
motor neuron
significantly
fatigue while
excitability.
increased MVC
supramaximal
to fatigue
shocks were
(p<0.05) predelivered every
to-post test. No
10 seconds
change
observed with
placebo.
Caffeine had
no effect on
twitch
amplitude
during MVC,
Average motor
unit firing rates
and Surface
EMG during
submaximal
contractions or
Alpha motor
neuron
excitability
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Table 3.3 (Continued Examining the purported mechanisms for ergogenic benefits observed with caffeine
supplementation (All studies either observed a significant performance effect with caffeine (p<0.05) or
only reported metabolic data*)
Publication
Subjects
Caffeine Dose Protocol
Mechanism
Key Results
Observed
Tarnopolsky et Healthy (12
6 mg/kg (100
2:00 tetanic
Yes (only at
Caffeine
al (102) 2000
male)
minutes prestimulation of
20Hz
significantly
exercise)
the peroneal
compared to
potentiated
nerve at 20Hz
placebo)
force of
and 40Hz.
contraction at
MVC and Peak
20Hz (p<0.05).
Twitch Torque
Caffeine had
of dorsiflexorss
no effect at
measured
40Hz or on
before and
MVC or Peak
after tetanic
Twitch Torque
stimulation.
Meyers et al
(76) 2005

10 male

6 mg/kg (1
hour preexercise)

Subjects
performed 50%
MVC of
quadriceps to
fatigue with
2.5 seconds
rest between
contractions
lasting 15
seconds.
Maximal
twitches
evoked during
2.5 second rest
periods.
Supramaximal
shocks
delivered
during 50%
contraction.

Yes (compared
to placebo for
MVC to
fatigue)
No (compared
to placebo)

Caffeine
significantly
increased MVC
to fatigue by
20.5 ± 8.1%
(p<0.05)
Caffeine had
no effect on
Motor Unit
Firing Rates or
Voluntary
Muscle
Activation
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Table 3.3(Concluded) Examining the purported mechanisms for ergogenic benefits observed with caffeine
supplementation (All studies either observed a significant performance effect with caffeine (p<0.05) or
only reported metabolic data*)
Publication
Subjects
Caffeine Dose Protocol
Mechanism
Key Results
Observed
Del Coso et al
Endurance
6 mg/kg in
120:00 cycling Yes (in all
Caffeine
(26)
Trained (7
capsule 45:00
at 63 ± 5%
caffeine trials
maintained
2008
male)
prior to
VO2max in a
vs. nonMVC isometric
exercise when
hot chamber
caffeine trials
torque and
used:
set at 36 ± 3 º
for both MVC
quadriceps
A=no fluid
C with 29 ±
isometric
voluntary
replacement
3% Humidity
torque and
activation
B=no fluid
and 1.9
voluntary
significantly
replacement +
m/second
activation)
better (p<0.05)
Caffeine
constant
than nonC=fluid
airflow. Pre
caffeine trials
replacement
(prior to
pre-to-post test.
with water
caffeine
Note: MVC
D=fluid
ingestion) and
isometric
replacement
Post Test MVC
torque and
with water +
isometric
quadriceps
Caffeine
torque and
voluntary
E=fluid
Pre/Post
activation did
replacement
quadriceps
decrease from
with 6% CHO
voluntary
pre-to-post test
+electrolyte
activation
in all trials.
solution
measured
F=fluid
replacement
with 6%CHO
+electrolyte
solution +
Caffeine
Note: VO2max=maximal oxygen consumption; VO2peak=maximal oxygen consumption for that specific
mode of exercise; FFA=free fatty acid; RER=respiratory exchange ratio; CHO=carbohydrate; CNS=central
nervous system; RPE=rating of perceived exertion; EMG=electromyographic

Differences in individual response to caffeine:
An interesting finding in studies that have reported individual results is that some
individuals fail to positively respond to caffeine (Table 3.4). Approximately 42% of all
subjects (including all trials/protocols) from those studies either displayed a negative
effect or no statistical change in performance with caffeine supplementation. Yet all the
studies except three (3,28,50), reported a significant performance effect with caffeine
(p<0.05). In addition, although Astorio et al (3) did not report a significant effect as a
result of caffeine supplementation, approximately 50% of their subjects improved their 1
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repetition maximum bench press and leg press as based on pre-established criteria.
Likewise, although Desbrow et al (28) failed to find a difference (p>0.05) in a 7 kJ/kg
cycling time trial performance between 1.5 mg/kg or 3 mg/kg caffeine doses compared to
a placebo; 5 of the 9 subjects improved performance following ingestion of the 3 mg/kg
dose compared to a placebo and 4 of 9 subjects improved performance following
ingestion of the 1.5 mg/kg dose compared to a placebo. Finally, Greer et al (50) did not
find a statistical effect (p>0.05) on either peak power or mean peak power during a 30
second Wingate test following caffeine supplementation; yet 12 of 18 subjects increased
their peak power and 11 of 18 subjects increased their mean peak power following
caffeine supplementation. The potential for differences in individual response patterns to
caffeine supplementation also does not appear to be mode or intensity specific; based on
the varying protocols of studies included in Table 3.4. One theory for differences in
individual response to caffeine supplementation is habitual caffeine use. The rationale
behind this theory is due to research associating caffeine tolerance with an increase in
adenosine receptor activity and a diminished β-adrenergic activity (20, 47, 71). However,
Doherty and Smith (31), in a recent meta-analysis concluded that period of subject
withdrawl from caffeine did not appear to have any major influence on the effects of
caffeine on RPE. Additionally, a study by Van Soren et al(105) from Table 3.2, did report
an increase in time to exhaustion (+ 6 minutes) with 6 mg/kg of caffeine following 2 or 4
days of withdrawl compared to 0 days withdrawl, but there was no statistical difference
between treatments and all 3 were significantly (p<0.05) better than the placebo.
Likewise, Wiles et al (108) reported improved performance following caffeine
supplementation did not appear to be influenced by habitual caffeine use. Thus a specific
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cause, if any, for the difference in individual responses to caffeine has yet to be
determined.
A recent study from our laboratory attempted to address a potential genetic link
involving a polymorphism of the Cytochrome P450 1A2 (CYP1A2) gene (110).
Approximately 95% of caffeine is metabolized in the liver by CYP1A2 (52, 67, 89).
Research has shown that wide inter-individual differences in caffeine metabolism can
occur as a result of variations in CYP1A2 activity (53, 67, 79). More specifically, an A
(adenine nucleotide)→C (cytosine nucleotide) substitution at position 734 in the
CYP1A2 gene creates the F allele (53,93). The resulting CYP1A2 polymorphism
presents itself as either an A allele or an F allele (53,93). Carriers of the F allele (C
variant) have a slow caffeine metabolism and link between caffeine intake and non-fatal
myocardial infarction whereas carriers of the A allele (A variant) have a fast caffeine
metabolism (19, 53, 93). In our prior study, we were able to group subjects according to
whether or not they were carries of the C variant. All subjects (11=A variant, 13=C
variant) in the study underwent both a short duration cycling test to fatigue and a 40
kilometer cycling time trial following 6mg/kg of caffeine ingestion one hour prior to
exercise. Although no significant effect (p=0.09) on short duration time to exhaustion
was observed following caffeine supplementation, a strong trend (p=0.06) was observed
for greater improvement in time to exhaustion for the A variant group (114.5 ± 37.9
seconds) compared to the C variant group (96.6 ± 25.4 seconds). Individually, 7 of 11
subjects in the A variant group were considered responders to caffeine and 5 of 13
subjects in the C variant group were considered responders to caffeine based on a criteria
of a 5% increase in time to exhaustion. Caffeine supplementation resulted in a significant
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(p<0.05) reduction in 40k time trial time for the A variant group whereas it had no effect
(p>0.05) on the C variant group. Individually, 7 of 11 subjects in the A variant group
were considered responders to caffeine (based on 5% reduction in time to completion) as
compared to 2 of 13 subjects from the C variant group. Additionally, none of the subjects
in the A variant group had a slower 40k time following caffeine supplementation yet 4
subjects in the C variant group did. Likewise, 10 of 11 subjects in the A variant group
improved their 40k time by at least 1:00 following caffeine supplementation while only 5
of 13 subjects in the C variant group did the same. In light of the fact the A variant group
significantly improved their 40k time while the C variant did not, in addition to the A
variant group displaying a stronger trend for improved time to exhaustion in the short
duration trial compared to the C variant group; the results from this study lend support to
a plausible connection regarding the effects of caffeine supplementation and the CYP1A2
polymorphism (110)
Table 3.4 Individual data for responders/non-responders to caffeine
Publication
Cycling
Jackman et al
(59)
1996

Greer et al
(50)
2006

Subjects

Caffeine Dose

Protocol

#Responders/Nonresponders

Key Results

Recreational
or athletically
trained (11
male, 3
female)

6 mg/kg (1
hour preexercise)

2:00 cycling at
power output
=VO2max6:00 rest.
Repeat.
Exercise at
same power
output to
exhaustion

10 responders and
4 non-responders

Caffeine
improved time
to exhaustion
vs. placebo
(p≤0.05), but
4 of 14
subjects didn’t
improve with
caffeine

Recreationally
active (18
male)

5 mg/kg (1
hour preexercise)

30 Second
Wingate Test

Peak Power: 12
responders and 6
non-responders
Mean Peak Power:
11 responders and
7 non-responders

Caffeine had
no effect on
mean or peak
power vs.
placebo yet 12
subjects
improved peak
power and 11
mean power
with caffeine
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Table 3.4 (Continued) Individual data for responders/non-responders to caffeine
Publication

Subjects

Womack et
al (110)
2007

Trained
cyclists (24
male) The
subject were
divided into
two groups:
Group A
(n=11) was
classified as
homozygous
for A
variant and
Group C
(n=13) was
classified as
homozygous
for C variant
of
Cytochrome
P450 gene1

Caffeine
Dose
6 mg/kg
(1 hour
preexercise)

Protocol
Short duration test: Cycle
to fatigue at
workload=150%VO2peak.
Different day: 40kilometer
cycling time trial

#Responders/Nonresponders
Short duration test:
12 responders and
12 non-responders
(based on criteria
of 5%
improvement in
time)
Time Trial: 9
responders and 15
non-responders
(based on criteria
of 5%
improvement in
time)

Key Results
Short
duration
test: all
subjects:
caffeine
demonstrated
a trend
toward
significance
(p=0.09) for
improving
time to
exhaustion.
Also group
A showed
stronger
trend for
improvement
(p=0.06) 7 of
11 in group
A responders
and 5 of 13
group C
responders.
Time trial:
Caffeine
significantly
improved
group A time
(p<0.05) but
had no effect
on group C
(p>0.05) vs.
placebo.
Group A
subjects all
improved
time with
caffeine and
10 of 11
improved by
at least 1:00.
In Group C
only 9 of 13
subjects
improved
with caffeine
and only 5 of
13 improved
by more than
1:00.
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Table 3.4 (Continued) Individual data for responders/non-responders to caffeine
Publication

Subjects

Jenkins et al
(61)
2008

Trained
cyclists (13
male)

Desbrow et al
(28)
2009

Trained
cyclists or
triathletes (9
male)

Caffeine
Dose
1 mg/kg, 2
mg/kg, or 3
mg/kg +
450ml water
(1 hour preexercise)

Protocol

1.5 mg/kg or
3 mg/kg (1
hour prior to
exercise)

120 Minutes
steady state
cycling at
70%
VO2peak
followed by
cycling Time
trial equal to
set amount of
work ~25-30
minutes.

15:00 cycling
at 80%
VO2peak.
4:00 active
recovery.
Maximal
effort cycling
for 15:00

#Responders/Nonresponders
1mg/kg: 5
responders and 8
non-responders.
2mg/kg: 11
responders and 2
non-responders
3mg/kg: 11
responders and 2
non-responders

Key Results

3 mg/kg: 5
responders and 4
non-responders
1.5 mg/kg: 4
responders and 5
non-responders

Caffeine had no
effect on time
trial
performance
(p>0.05) with
either dose yet 5
of 9 subjects
improved with
3 mg/kg and 4
of 9 with 1.5
mg/kg vs.
placebo

Among all
subjects: 1
mg/kg caffeine
did not
statistically
differ from
placebo,
however 5 of 13
did improve
with caffeine.
2mg/kg did
statistically
improve
performance
(p=0.02) but
only 11 of 13
actually
improved. 3
mg/kg trended
to significantly
improving
performance
(p=0.077) but
only 11 of 13
actually
improved
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Table 3.4 (Continued) Individual data for responders/non-responders to caffeine
Publication

Subjects

Caffeine
Dose

Protocol

#Responders/Nonresponders

Key Results

Running
Wiles et al
(108)
1992

Trained
runners (18
male)

3 grams of
coffee (150200 mg
caffeine)
+350ml hot
water (1 hour
pre-exercise)

1500 meter
time
trial (3 trials
performed and
the mean
value taken)

14 responders and
4 non-responders

Resistance
Exercise
Meyers et al
(76)
2005

Among all
subjects
caffeine
significantly
(p<0.05)
improved time
by 4.2 seconds
yet 4 subjects
performed
worse
following
caffeine use

10 male

6 mg/kg (1
hour preexercise)

50% MVC of
quadriceps to
fatigue for 15
seconds with
2.5 seconds
rest between
contractions.
Maximal
twitches
evoked during
2.5 second
rest periods.
Supramaximal
shocks
delivered
during 50%
contraction

MVC to fatigue:7
responders, 2 nonresponders, 1
subject did
performed worse
with caffeine

Among all
subjects:
caffeine
significantly
improved MVC
to fatigue by
20.5 ± 8.1%
(p<0.05)
however 3 of
10 subjects
either displayed
no change or a
negative
change in
performance
with caffeine
compared to
placebo.

Hudson et al
(56)
2008

Moderately
trained (15
male)

6mg/kg + 500
ml water (1
hour preexercise)

Leg
extension: 4
sets to failure
at weight =12
repetition
maximum
with 3:00 rest
between sets.
Arm Curls:
same as above

Leg extension: 7
responders and 8
non-responders
Arm Curls: 8
responders and 7
non-responders
Note: response/noresponse criteria
based on ≥5
repetition
improvement with
caffeine
supplementation

All subjects:
caffeine
(p<0.05)
increased total
repetitions
performed in
the leg press
and trended to
significance for
total repetitions
performed for
arm curls
(p=0.051) yet
in both groups
the # of
responders/nonresponders was
~50/50 split
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Table 3.4 (Concluded) Individual data for responders/non-responders to caffeine
Publication

Subjects

Astorio et al
(3)
2008

Resistance
trained (22
male)

Caffeine
Dose
6 mg/kg (1
hour preexercise)

Protocol
1 repetition
maximum
bench press
and leg press

#Responders/Nonresponders
Bench press: 12
responders and 10
non-responders
(based on criteria
of lifting at least 3
kg more with
caffeine)
Leg Press: 11
responders and 11
non-responders
(based on criteria
of lifting at least 10
kg more with
caffeine)

Key Results
Among all
subjects
caffeine had no
statistical effect
on maximal
bench press
(116.4 ± 23.6
kg) vs. placebo
(114.9 ± 22.8
kg) (p>0.05)
yet 12 of 22
subjects
improved with
caffeine.
Among all
subjects
caffeine had no
statistical effect
on maximal leg
press (410.6 ±
92.4 kg) vs.
placebo (394.8
± 95.4 kg)
(p>0.05) yet 11
of 22 subjects
improved with
caffeine.

Note: 1For more information on Cytochrome P450 gene see text; VO2max=maximal oxygen consumption;
VO2peak=maximal oxygen consumption for that specific mode of exercise; MVC=maximal voluntary
contractions

Influence of dosage amount, timing of ingestion, and training status on
performance:
Research suggests the optimal effective dose for caffeine supplementation may be
~5-6 mg/kg (1,3,5,6,13,18,22,27,32,41,49,56,57,59,66,74,75,82,95,100,105,107).
Additionally, a review of 21 studies by Ganio et al (40) led the authors to suggest that
dosage amounts between 3 and 6 mg/kg are commonly demonstrated to enhance
endurance performance. However, few studies have compared the ergogenic effects of
different dosage amounts (Table 3.5) on the same group of subjects.
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Studies that have reported a dose-response effect, generally found the effect with
dosage amounts less than ~ 3 mg/kg. For example, Kovacs et al (70), reported significant
improvement (p<0.01) in a cycling time trial with caffeine doses of ~2.1 mg/kg, ~3.2
mg/kg, and ~4.5 mg/kg compared to a placebo. There was no difference in performance
between the ~3.2 mg/kg and ~4.5 mg/kg doses, however they both resulted in a
significantly (p<0.01) better performance than the ~2.1mg/kg dose. Similarly, Jenkins et
al (61) compared 15:00 of maximal effort cycling performance using 1 mg/kg, 2 mg/kg,
or 3 mg/kg doses. The 2 mg/kg dose statistically (p=0.02) improved performance
compared to the placebo, the 3 mg/kg dose trended (p=0.077) to improved performance
compared to the placebo and the 1 mg/kg dose did not improve (p>0.05) performance
compared to the placebo. However there were no differences (p>0.05) in performance
between the 2 mg/kg or 3 mg/kg trial. Likewise, Cadarette et al. (15) reported a
significant (p<0.05) improvement in time to fatigue on a treadmill run at ~80% VO2max
with a 4.4 mg/kg dose ,but not a 2.2 mg/kg dose, compared to a placebo. Although the
authors reported no statistical (p>0.05) difference between time to exhaustion following
the 4.4 mg/kg dose and the 2.2 mg/kg dose, the 4.4 mg/kg did increase time to exhaustion
by 5.6 minutes compared to the 2.2 mg/kg dose. Finally, although Desbrow et al (28)
failed to find a difference (p>0.05) in a 7 kJ/kg cycling time trial performance between
1.5 mg/kg or 3 mg/kg caffeine doses compared to a placebo; 5 of the 9 subjects
performed better following ingestion of the 3 mg/kg dose while only 2 subjects each
performed better with the 1.5 mg/kg dose or placebo respectively.
In a recent review Burke (14) notes that there does not appear to be a doseresponse effect (leading to enhanced performance) with caffeine beyond a dose of ~3
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mg/kg. In support of this, Kang et al (66) reported a significant improvement (p<0.05) in
a 30 second Wingate test with both a 2.5 mg/kg and 5.0 mg/kg caffeine dose compared to
a placebo, but reported no difference between treatments. Likewise, Passman et al (86)
reported a significant (p<0.05) improvement in cycling time to exhaustion at 80% Wmax
with caffeine doses of 5, 9, and 13 mg/kg with no difference between treatments. Finally,
Bruce et al (13) reported a significant (p<0.05) improvement in a 2000 ergometer rowing
time trial following ingestion of both 6 mg/kg and 9 mg/kg doses of caffeine compared to
a placebo, with no difference between treatments. These studies, as well as studies by
Kovacs et al (70), and Graham and Spriet (46) seem to suggest a lack of a dose-response
relationship beyond ~3mg/kg of caffeine.
However, the study by Graham and Spriet (46) compared 3, 6, and 9 mg/kg doses
to a placebo on treadmill run time to exhaustion at ~85% VO2max and reported a
significant (p<0.05) improvement with both the 3 and 6 mg/kg doses compared the
placebo. Although no significant differences were found between the caffeine
treatments, the 9 mg/kg dose did not result in a statistically significant (p>0.05)
improvement compared to the placebo. Likewise, Cadarette et al (15) reported no
statistical difference between a 4.4 mg/kg or 8.8 mg/kg dose on treadmill run time to
fatigue at 80% VO2max yet only the 4.4 mg/kg dose resulted in a statistically significant
(p<0.05) increase in performance compared to the placebo. Therefore potentially
suggesting a negative effect may occur with dosage amounts greater than ~6mg/kg.
Thus it appears a dose-response effect may occur with dosage amounts less than
~3 mg/kg such that dosage amounts less than ~3mg/kg may not be as effective as dosage
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amounts greater than ~3mg/kg. Likewise dosage amount greater than 6 mg/kg may also
result in a reduced performance.
Peak plasma caffeine concentration is thought to occur 30-60 minutes following
oral ingestion of caffeine (18,22). This logically suggests maximal performance effects
should occur ~1 hour following caffeine ingestion (11, 38, 42). In fact, a majority of the
studies reviewed in tables 3.1 and 3.2 used 1 hour pre-exercise as their benchmark for
caffeine ingestion. However only 3 of the studies (Table 3.5) actually compared multiple
timing protocols with regards to ingestion of caffeine (6,18,22). Bell et al (6) reported a
significant (p≤ 0.05) improvement in time to exhaustion at 80% VO2 peak following
caffeine ingestion 1, 3 and 6 hours prior to exercise with no significant differences
between protocols among all subjects. However when subjects were classified as users
(n=13, ≥300 mg caffeine/day) and non-users (n=8, <50mg caffeine/day), only the nonusers demonstrated a significant performance improvement following caffeine ingestion
6 hours prior to exercise. Conway et al (18) reported a non-significant (p=0.08)
improvement in time trial performance with both caffeine ingestion of either 6 mg/kg 1
hour pre-exercise or 3 mg/kg 1 hour pre-exercise and 3 mg/kg 45:00 into exercise.
Although not significant (p>0.05), the single dose of caffeine resulted in a 48 second
(23.4 min vs. 24.2 min) improvement in time trial performance. Cox et al (22) reported a
significant improvement(p=0.04) in time trial performance (3.4%) following 120 minutes
of steady state(SS) cycling at 70% VO2peak with caffeine ingestion of 6 mg/kg 1 hour
pre-exercise; whereas caffeine ingested in either 6 x 1 mg/kg doses every 20:00
throughout the SS or in 2 x 5 ml/kg doses of coca cola (total caffeine=1.3 mg/kg)
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ingested in the final 20 minutes of SS and during the time trial resulted in a nonsignificant (p=0.06) trend toward improvement (3.1%).
Finally, the ergogenic effects of caffeine may be influenced by the training status
of the subjects used (7). For example, Collomp et al (17) reported a significant (p<0.01)
improvement in 100 meter swim time in trained subjects, but not in untrained subjects,
following caffeine supplementation. However, Kang et al (66) did not find a difference in
performance on a 30 second Wingate test between professional cyclists and PE students
following caffeine supplementation. Likewise, O’Rourke et al (82) did not find a
difference in 5 kilometer running time between well trained runners and recreational
runners (mostly team sport-athletes) following caffeine supplementation. The lack of
studies comparing the response of trained vs. untrained subjects does not allow for a
feasible conclusion; however it is certainly area that could use more research.
Table 3.5 Influence of dosage amount, timing of ingestion, and training status on performance
Publication

Subjects

Caffeine Dose

Protocol

Influence
Observed

Key Results

Well trained
cyclists (9, no
data for M/F)

5 mg/kg, 9
mg/kg or 13
mg/kg (1 hour
prior to
exercise with
water)

Cycle at 80%
Wmax until
exhaustion

No (all 3 doses
improved
performance
vs. placebo
(p<0.05) with
no differences
between them)

5mg/kg=58 ± 11
9mg/kg=59 ± 12
13mg/kg=58±12
Placebo=47±13
(Minutes to
exhaustion)

Multiple
Doses
Cycling
Passman et al
(86)
1995
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Table 3.5 (Continued) Influence of dosage amount, timing of ingestion, and training status on performance
Publication

Subjects

Caffeine Dose

Protocol

Kang et al (66)
1998

Professional
Cyclists (7) PE
students (7)

2.5 mg/kg or
5.0 mg/kg
(prior to
exercise)

30 second
Wingate Test

Influence
Observed
No. Both doses
improved
performance
with no
difference
between them

Key Results
Professional
cyclists:
Caffeine
significantly
(p<0.05)
increased peak
power
(2.5mg=969 ±
67 W,
5.0mg=947 ±
93 W) vs.
placebo (845 ±
120W) as well
as mean power
(2.5mg=819 ±
87W,
5.0mg=826 ±
92W ) vs.
placebo (715±
85W)
PE Students:
Caffeine
significantly
(p<0.05)
increased peak
power (2.5
mg=823 ±
45W,
5.0mg=837±
94W) vs.
placebo (784 ±
79) as well as
mean power
(2.5mg=660±
62W, 5.0
mg=676± 68
W) vs.
placebo(625 ±
79W)
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Table 3.5 (Continued) Influence of dosage amount, timing of ingestion, and training status on performance
Publication

Subjects

Caffeine Dose

Protocol

Influence
Observed
Yes (all
caffeine trials
C,D,E
compared to
placebo A)
But, caffeine
trials D,E
better than C

Key Results

Kovacs et al
(70)
1998

Trained
Cyclists (15
male)

A=placebo (14
total ml/kg fluid)
B=7%
CHO+electrolyte
solution
(CES)+0caff
C=CES +
~2.1ml/kg
D=CES +
~3.2ml/kg
E=CES +
~4.5ml/kg.
Consumed
8ml/kg fluid
55:00 prior to
test, then 3
ml/kg at 20 and
40 minutes of
exercise

Time Trial to
complete set
amount of
work
J=0.75wmax x
3,6000

Jenkins et al
(61)
2008

Trained
Cyclists (13
male)

1 mg/kg, 2
mg/kg, or 3
mg/kg (1 hour
pre-exercise and
all with 450 ml
water)

15:00 cycling
at 80%
VO2peak
followed by
4:00 active
recovery,
followed by
maximal effort
cycling for
15:00

Yes (2mg/kg
and 3mg/kg
improved
performance
but 1 mg/kg
did not)

2 mg/kg and
3mg/kg
caffeine
significantly
improved work
performed by
4% (p=0.02)
and by 3% vs.
placebo
(p=0.077)
respectively.
1mg/kg didn’t

Desbrow et al
(28)
2009

Trained
cyclists or
triathletes (9
male)

1.5 mg/kg or 3
mg/kg (1 hour
prior to exercise)

120:00 Steady
state cycling at
70% VO2peak
followed by
Time Trial to
complete set
amount work
(~25:00-30:00)

No? Neither
dose improved
performance
vs. placebo
(p>0.05)

No statistical
improvement,
but 5 of 9 had
best time with
3 mg/kg dose
vs. 2 of 9 with
1.5 mg/kg
dose.

All caffeine
trials
significantly
increased work
output (W) and
significantly
decreased TT
time to
completion
compared to
placebo
(p<0.01). Also,
Trial D (58.9 ±
1.0 min, 308 ±
9 W) and Trial
E (58.9± 1.2
min, 309 ± 10
W)
significantly
better (p<0.01)
than trial A
(62.5 ± 1.3
min, 292 ± 10
W) trial B
(61.5 ± 1.1
min, 295 ± 9
W), and trial C
(60.4 ± 1.0
min, 299 ±
10W)
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Table 3.5 (Continued) Influence of dosage amount, timing of ingestion, and training status on performance
Publication
Rowing
Bruce et al (13)
2000

Anderson et al
(1) 2000

Running
Cadarette et al
(15) 1982

Graham and
Spriet (46)
1995

Subjects

Caffeine Dose

Protocol

Influence
Observed

Key Results

Well trained
rowers (8
male)

6mg/kg or
9mg/kg (90:00
pre-exercise)

2000 meter
ergometer row

No(both doses
improved
performance,
but no
difference
between them)

6mg/kg
improved
performance by
mean of 1.3%
(p=0.01) and
9mg/kg by
mean of 1.1%
(p=0.03)

Well trained
rowers (8
female)

6mg/kg or
9mg/kg (90:00
pre-exercise)

2000 meter
ergometer row

Yes? (both
doses improved
performance
with no
difference
between them,
but only
9mg/kg was
significant

6mg/kg
(p=0.06) and
9mg/kg
(p=0.005)
improved
performance by
mean of 0.7%
and 1.3%
respectively

Recreationally
trained runners
(4 male, 4
female)

2.2 mg/kg, 4.4
mg/kg, or 8.8
mg/kg with
250 ml
lemonade (~1
hour preexercise)

Treadmill run
to fatigue at
~80% VO2max

Yes? (all 3
doses improved
performance
vs. placebo, but
only 4.4 mg/kg
dose was
significant
(p<0.05) vs.
placebo)

Time to
exhaustion in
minutes:
Placebo: 53.4
2.2 mg/kg:
67.8
4.4 mg/kg:
73.4
8.8 mg/kg:
57.9
No significant
differences
between
(p>0.05) doses

Well trained
distance
runners (8
male)

3 mg/kg, 6
mg/kg, or 9
mg/kg (1 hour
pre-exercise)

Treadmill run
to exhaustion
at ~85%
VO2max

Yes? (all 3
doses improved
performance
vs. placebo, but
only 3 and 6
mg/kg were
significant
(p<0.05) vs.
placebo)

Percent
improvement
vs. placebo:
3 mg/kg: 22.0
± 9%
6 mg/kg: 21.9
± 7.2%
9 mg/kg: 10.9±
12.6 %. No
difference
between 3
treatments
(p>0.05)
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Table 3.5 (Continued) Influence of dosage amount, timing of ingestion, and training status on performance
Publication

Subjects

Caffeine Dose

Protocol

Influence
Observed

Key Results

Aerobically
Active (15
male, 6 female)

5mg/kg (1,3, or
6 hours preexercise) All
trials also
consumed
5mg/kg
Gatorade 1
hour before
exercise

Cycle to
exhaustion at
80% VO2peak

No (all timing
protocols
improved
performance,
but no
difference
between them)

All Caffeine
trials
significantly
improved time
to exhaustion
(28.8 ±8.6
minutes ) vs.
(24.0 ± 6.5)
(p≤0.05)

Cox et al (22)
2002

Trained
cyclists and
triathletes (12
male)

A=6 mg/kg 1
hour preexercise
B=6x1mg/kg
doses every
20:00 of
exercise
C=Placebo
D=2x5ml/kg
Coca Cola
instead of
sports drink
(=1.3 mg/kg
caffeine
All trials
(except D)
provided sports
beverage
throughout trial
=2.1g/kg of
CHO

120 minutes
cycling at 70%
VO2peak
followed by
time to
completion TT
=7kj/kg

Yes? (All
timing
protocols
improved
performance
but only Trial
A was
significant)

Trial A
significantly
improved time
to completion
by 3.4% vs.
Trial C
(p=0.04) Trial
B&D
improved time
to completion
by 3.1% vs.
Trial C and
trended to
significance
(P=0.06)

Conway et al
(18)
2003

Trained
cyclists and
triathletes (9
male)

A=6mg/kg 1 hr
pre-exercise
B= 3mg/kg 1
hr pre-exercise
and 3mg/kg
45:00 into
exercise

90:00 cycling
at 70%
VO2max
followed by
time trial at
80% VO2max

No (no
significant
difference in
performance
between timing
protocols)

Timing of
Ingestion
Cycling
Bell et al (6)
2002

Both caffeine
trials improved
performance of
TT (23.8 ± 2.8
minutes vs.
28.3 ± 3.1)
(p=0.080)
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Table 3.5 (Continued) Influence of dosage amount, timing of ingestion, and training status on performance
Publication
Training
Status
Cycling
Kang et al (66)
1998

Swimming
Collomp et al
(17) 1992

Subjects

Caffeine Dose

Protocol

Influence
Observed

Key Results

Professional
cyclists (7) PE
students (7)

2.5 mg/kg or 5
mg/kg (prior to
exercise)

30 second
Wingate Test

No. Both
groups of
subjects
improved
performance
with no
difference
between them

Professional
cyclists:
Caffeine
significantly
(p<0.05)
increased peak
power
(2.5mg=969 ±
67 W,
5.0mg=947 ±
93 W) vs.
placebo (845 ±
120W) as well
as mean power
(2.5mg=819 ±
87W,
5.0mg=826 ±
92W ) vs.
placebo (715±
85W)
PE Students:
Caffeine
significantly
(p<0.05)
increased peak
power (2.5
mg=823 ±
45W,
5.0mg=837±
94W) vs.
placebo (784 ±
79) as well as
mean power
(2.5mg=660±
62W, 5.0
mg=676± 68
W) vs.
placebo(625 ±
79W)

Trained
swimmers (3
male, 4 female)
Untrained
swimmers (2
male, 5 female)

250 mg (4.3 ±
0.2 ml/kg) 1
hour preexercise

2 x 100 meters
freestyle,
maximum
effort swim
separated by
20:00 passive
recovery

Yes (Caffeine
improved
performance in
trained but not
untrained

Trained:
Caffeine
significantly
(p<0.01)
improved mean
velocity
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Table 3.5 (Concluded) Influence of dosage amount, timing of ingestion, and training status on performance
Publication
Running
O’Rourke et al
(82)
2008

Subjects

Caffeine Dose

Protocol

Influence
Observed

Key Results

Well Trained
Runners (15,
no data given
for M/F)
Recreational
runners (15, no
data given for
M/F)

5 mg/kg (1
hour preexercise)

5 Kilometer
Running Trial

No (no
difference in
improvement
between
groups)

Caffeine
significantly
improved
running
performance in
both groups
(p<0.01). Well
trained group
improved by
1% and
recreational
group
improved by
1.1%

Notes:W=Watts;VO2max=maximal oxygen consumption;VO2peak=maximal oxygen consumption for that
specific mode of exercise;Wmax=maximal power output

Summary:
In conclusion, caffeine is a proven ergogenic aid for endurance performance and
research also indicates it may provide ergogenic benefits for short-term, high intensity
exercise as well. A majority of studies suggest the optimal time for ingestion of caffeine
is 1 hour pre-exercise, likely due to the fact peak plasma caffeine levels occur ~30:0060:00 minutes after ingestion. Additionally, the optimal dosage amount appears to be in
the range of ~3 to ~6mg/kg although doses above and below those amounts have
demonstrated ergogenic effects. While the exact mechanism(s) through which caffeine
exerts its ergogenic effects are unclear, research suggests caffeine’s actions on the central
nervous system and/or sarcoplasmic recticulum may be a leading cause. However there
are still relatively few studies exploring the ergogenic benefits of caffeine in relation to
issues such as training status, dose-response effect, caffeine habituation, and actual field
studies (as compared to lab studies). Recent research also indicates variation in
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individual response to caffeine that may in part be due a CYP1A2 Polymorphism.
Therefore, while the ergogenicity of caffeine has been well established, future research
should examine physiological mechanisms and other factors (training status, genotype,
sex) that will help to optimize caffeine supplementation in an individual manner.

CHAPTER 3: METHODOLOGY
Subjects: 16 male, recreationally competitive cyclists were recruited for this study (age
=26.4 ± 7.4 yrs, height = 176.6 ± 6.8 cm, weight = 71.8 ± 7.8 kg, VO2max =64.7 ± 9.1
ml/kg/min). Subjects were healthy, free from known disease, and free from medications.
Informed consent was obtained from all subjects prior to participation per the James
Madison University Institutional Review Board.

Maximal Exercise Test: Subjects performed an exercise test to exhaustion to determine
maximal oxygen consumption. The test began at a work rate of 150 W on an indoor
cycle trainer (Racermate Veletron: Seattle, WA), with load increases of 20 W each
minute until volitional exhaustion. The highest 1-minute oxygen uptake value obtained
during the test was defined as peak oxygen uptake (VO2peak). The highest power output
obtained during the test was defined as peak power output (POpeak). Oxygen uptake was
monitored continuously via a Sensormedics Vmax (Yorba Linda, CA) metabolic
measurement system calibrated in advance of all tests. Heart rate was monitored using a
Polar Heart Rate Monitor (Lake Success, NY).

40 Kilometer Time Trials: All subjects were tested on 4 separate occasions separated by
a minimum of 5 full days and a maximum of 10 days. The first trial served as a
familiarization trial and the remaining trials as treatments. All testing occurred in the
morning following a 10 hour fast and 24 hour abstinence from caffeine ingestion. One
hour prior to testing, subjects ingested either a placebo, 3mg/kg caffeine, or 6 mg/kg
caffeine capsule administered in double-blind fashion along with 22 ounces of a 6%
carbohydarate/electrolyte solution. The order of testing for different dosages was
counterbalanced. Time trials were performed on an indoor cycle trainer (Racermate
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Velotron: Seattle, WA) on a computer-simulated course. The course consisted of eight
laps of a flat, five-kilometer loop. Subjects were allowed to observe distance completed
on the course via a video display, but were blinded from any performance indicators,
including power output, lap time and total time. In addition, no data from the trials was
provided until subjects completed the entire study. Oxygen uptake (VO2), respiratory
exchange ratio (RER), heart rate (HR), and Ratings of Perceived Exertion (RPE), using
the original Borg scale, were obtained at 10km intervals throughout the trial.

Statistical Analyses: Potential differences in 40K time, average power output (Watts),
HR, RPE, VO2, and RER were assessed using repeated measures ANOVA with treatment
as a within-subjects factor. A priori level of significance was set at p<0.05. Any
significant differences were analyzed using a dependent t-test with a Bonferroni
correction with the a-priori level of significance set at p<0.017. All data are reported as
means ± SD.

CHAPTER 4: RESULTS
40 Kilometer Time Trials:
Figure 1 displays average 40 kilometer time trial performance following each
treatment. Caffeine significantly (P<0.017) improved performance in the 3mg/kg (72.7 ±
4.6 min) and 6mg/kg (71.6 ± 4.7 min) trials compared to placebo (74.1 ± 5.4 min). There
was also a trend (P=0.04, Bonferroni correction) for enhanced performance for 6mg/kg as
compared to 3mg/kg
Average Power output, HR, RPE, VO2, and RER:
Table 1 displays average power output, HR, RPE, VO2 and RER for each of the
40k time trials. Average power data was able to be collected on only 12 subjects. Due to
technical difficulties, complete data for VO2 and RER was collected for only 9 subjects.
Average power output was significantly greater with 3mg/kg and 6 mg/kg compared to
placebo (P<0.017). The 6 mg/kg dose also resulted in a significantly (P=0.012) greater
average power output compared to the 3 mg/kg dose. Average HR was significantly
greater with 3mg/kg and 6mg/kg compared to placebo (P<0.017). The 6 mg/kg dose also
resulted in a trend (P=0.09) for a significantly greater average HR than the 3 mg/kgdose.
No significant differences occurred among treatments for average RPE, VO2 and
RER.
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Table 1: Average values for Power output, Heart Rate, Rating of Perceived Exertion, VO2, and Respiratory
Exchange Ratio for each of the three, 40 kilometer time trials.
3mg/kg
6mg/kg
Placebo
Power output (Watts)

191.4 ± 18.4*

202.2 ± 24.4*#

183.9 ± 18.9

HR

162.9 ± 11.9*

165.6 ± 12.9*

156.8 ± 14.1

RPE

15.1 ± 1.5

15.2 ± 1.5

15.1 ± 1.5

3.48 ± 0.6
(~76%VO2max)
0.89 ± 0.03

3.66 ± 0.6
(~80%VO2max)
0.88 ± 0.04

3.47 ± 0.7
(~75%VO2max)
0.89 ± 0.03

VO2 (L/min)
RER

* Significantly (P<0.017) different than placebo
# Significantly (P=0.012) different than 3mg/kg

Average 40K time per treatment
74.5

74.1

5.4

40 Kilometer Time (Minutes)

74
73.5
72.7

4.6 *

73
72.5

71.6

4.7*

72

Placebo
Low (3mg/kg)

71.5

High (6mg/kg)2

71
70.5
70
Placebo

3mg/kg

6mg/kg

Treatment
Figure 1: 40 Kilometer Time Trial Performance. *Statistical improvement in time compared to placebo
(P<0.017).

CHAPTER 5: DISCUSSION
Although doses of both 3 mg/kg and 6 mg/kg significantly improved 40 kilometer
time trial performance compared to a placebo, there was a trend (p=0.04, Bonferroni
correction) for a larger performance improvement with the 6 mg/kg dose. The
ergongenic effect of caffeine on performance found with both the 3 mg/kg and 6 mg/kg
doses is in agreement with previous research (2, 6,12,27,43,57, 74,75, 82,100, 105,107).
Our findings of a trend suggesting a dose-response relationship exists between
low and high doses of caffeine, such that the high dose further enhances performance, are
in contrast with previous research. In a recent review Burke (14) notes that there does
not appear to be a dose-response effect to caffeine beyond a dose of ~3 mg/kg. In
support of Burke’s hypothesis, Kang et al (66) reported a significant improvement
(p<0.05) in a 30 second Wingate test with both a 2.5 mg/kg and 5.0 mg/kg caffeine dose
compared to a placebo, but reported no difference between treatments. Likewise,
Passman et al (86) reported a significant (p<0.05) improvement in cycling time to
exhaustion at 80% Wmax with caffeine doses of 5, 9, and 13 mg/kg with no difference
between treatments. Finally, Bruce et al (13) reported a significant (p<0.05)
improvement in a 2000 ergometer rowing time trial following ingestion of both 6 mg/kg
and 9 mg/kg doses of caffeine compared to a placebo, with no difference between
treatments. These studies, as well as studies by Kovacs et al (70), and Graham and Spriet
(46) do seem to suggest a lack of a dose-response relationship beyond ~3mg/kg of
caffeine.
Interestingly, Graham and Spriet (46) compared 3, 6, and 9 mg/kg doses to a
placebo on treadmill run time to exhaustion at ~85% VO2max and reported a significant
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(p<0.05) improvement with both the 3 and 6 mg/kg doses compared the placebo.
However, although the 9 mg/kg dose did not result in a statistically significant (p>0.05)
difference in performance compared to either the 3 mg/kg or 6 mg/kg dose, it did not
improve performance (p>0.05) compared to the placebo. Likewise, Cadarette et al (15)
reported no statistical difference between a 4.4 mg/kg or 8.8 mg/kg dose on treadmill
time to fatigue at 80% VO2max: yet only the 4.4 mg/kg dose resulted in a statistically
significant (p<0.05) increase in performance compared to the placebo. Therefore, it is
possible that a negative dose-response occurs with dosage amounts greater than ~6mg/kg.
The results of our study, as well as the two aforementioned studies may indicate that ~56 mg/kg is indeed the optimal dose needed for improved performance. However, the
theory is only speculative at this point because we didn’t include a dose greater than 6
mg/kg to allow for comparison. Also, neither Anderson et al (1), Bruce et al (13), nor
Passman et al (86) reported a negative effect on performance with doses ≥ 9 mg/kg as
compared to doses ≤ 6 mg/kg.
Other prior research has reported a dose-response effect for improved
performance with increased dosages, but generally with dosage amounts less than ~ 3
mg/kg. Using an exercise protocol similar to ours, Kovacs et al (70), reported significant
improvement (p<0.01) in a cycling time trial with caffeine doses of ~2.1 mg/kg, ~3.2
mg/kg, and ~4.5 mg/kg compared to a placebo. There was no difference in performance
between the ~3.2 mg/kg and ~4.5 mg/kg doses, however they both resulted in a
significantly (p<0.01) better performance than the ~2.1mg/kg dose. Similarly, Jenkins et
al (61) compared 15:00 of maximal effort cycling performance using 1 mg/kg, 2 mg/kg,
or 3 mg/kg doses. The 2 mg/kg dose statistically (p=0.02) improved performance
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compared to the placebo, the 3 mg/kg dose trended (p=0.077) to improved performance
compared to the placebo and the 1 mg/kg dose did not improve (p>0.05) performance
compared to the placebo. However there were no differences (p>0.05) in performance
between the 2 mg/kg or 3 mg/kg trial. Likewise, Cadarette et al. (15) reported a
significant (p<0.05) improvement in time to fatigue on a treadmill run at ~80% VO2max
with a 4.4 mg/kg dose ,but not a 2.2 mg/kg dose, compared to a placebo. Although the
authors reported no statistical (p>0.05) difference between time to exhaustion following
the 4.4 mg/kg dose and the 2.2 mg/kg dose, the 4.4 mg/kg did increase time to exhaustion
by 5.6 minutes compared to the 2.2 mg/kg dose. Finally, although Desbrow et al (28)
failed to find a difference (p>0.05) in a 7 kJ/kg cycling time trial performance between
1.5 mg/kg or 3 mg/kg caffeine doses compared to a placebo; 5 of the 9 subjects
performed better following ingestion of the 3 mg/kg dose while only 2 subjects each
performed better with the 1.5 mg/kg dose or placebo respectively. Thus it appears
research suggests a dose-response effect may occur with dosage amounts less than ~3
mg/kg and perhaps with dosage amounts greater than ~ 6mg/kg; such that dosages above
or below those amounts may not improve performance to the degree dosage amounts
within ~3-~6 mg/kg improve performance.
To our knowledge only one other study (46) has directly compared caffeine
dosages within the range suggested (40,42) to be “optimal” (3 mg/kg-6mg/kg) needed for
ergogenic effects. The results of the study by Graham and Spriet, as described in the
previous paragraph, do not indicate a dose-response effect for greater performance with 6
mg/kg as compared to 3 mg/kg (46). Yet, differences in both study protocol (time to
exhaustion vs. time trial) and intensity (~85% VO2max vs. ~75-80% VO2max) as well as
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exercise mode (running vs. cycling) make it difficult to directly compare studies. For
example, time to exhaustion protocols may result in a large degree of intra and intersubject variability (40). In fact, Jeukendrup et al (62) reported a coefficient of variation
of 26.6% following 5 repeated trials of a time to exhaustion protocol whereas a time trial
protocol only resulted in a coefficient of variation of 3.4% over the course of 5 repeated
trials. Thus leading the authors to suggest that time trial protocols are not influenced by a
potential learning or order effect. Similarly, Palmer et al (83) reported a 1% coefficient
of variation for a laboratory 40k cycling trial. One other study (66) did use a dosage
protocol very similar (2.5 mg/kg, 5mg/kg, placebo) to ours. Again, the authors reported a
statistical improvement with caffeine (p<0.05) compared to placebo but did not find a
difference in performance between the two doses. The protocol used (30 second Wingate
Test) is vastly different from ours in terms of both duration and energy systems used
which again makes a direct comparison difficult. Finally, one other study used a similar
exercise mode and protocol to the present study as well as compared at least two dosage
amounts greater than ~ 3mg/kg (70). The authors failed to find a dose effect between
doses of ~3.2 mg/kg and ~4.5 mg/kg. However the subjects in that trial ingested the
caffeine in combination with a carbohydrate-electrolyte solution before, 1/3, and 2/3 of
the way through the time trial, thus making a direct comparison difficult.
Mechanisms:
A primary mechanism for improved performance observed with caffeine is
thought to be its effect on adenosine receptors. Adenosine receptors are known to limit
spontaneous and neurotransmitter-evoked firing of cortical neurons (33,72, 87) as well as
play a role in an increase in pain signaling during exercise (77,78,94). Because caffeine
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is an adenosine receptor antagonist (29,37,38,68,84,85,87,96), it has the ability to
decrease pain perception, and increase neuro-excitability, neurotransmitter release and
arousal (24, 63, 77, 78, 81, 94). This effect serves to reduce the perceptual response
(rating of perceived of exertion or RPE) in subjects to exercise, thus allowing them to
either exercise at a higher intensity or exercise longer at a fixed work rate (31 ,98). In
fact, a recent meta-analysis of 21 studies found that RPE during exercise was decreased
by 5.6% with caffeine compared to a placebo (31). Additionally, several studies have
reported the same absolute RPE at the end of exercise following both caffeine and
placebo trials yet the work performed was significantly greater following caffeine use
(13, 56, 61, 74, 95, 108). This suggests the subjects in those studies may have had a
reduced pain sensation or were able to recruit more motor units (31). Our study found no
differences in RPE (p>0.05) among treatments despite the fact that both caffeine trials
were significantly (p<0.017) faster than the placebo and the 6 mg/kg dose resulted in a
trend (p=0.04, Bonferroni correction) to a faster time than the 3 mg/kg dose. The lack of
difference in RPE also occurred despite a significant (p<0.017) increase in avearage
power output (n=12) and heart rate with both caffeine trials compared to the placebo trial.
Thus, it seems subjects may have experienced a reduction in pain sensation, or were able
to recruit more motor units at the same perceived level of work following caffeine
ingestion. It is plausible the higher dose of caffeine had a greater antagonistic effect on
adenosine receptors than the lower dose which could explain the observed trend towards
improved performance with the higher dose of caffeine, especially in light of the fact that
average power output was significantly (p=0.012) greater with the 6 mg/kg dose
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compared to the 3 mg/kg dose. However, data from the 3 dose-response studies that did
record subject RPE do not support this contention (13,15,61).
A recent study from our laboratory indicated a possible link between a CYP1A2
polymorphism (A/C) and the ergogenic effects of caffeine on performance (110). The
authors were able to classify 11 of 24 subjects as carriers of the A variant and the other
13 subjects as carriers of the C variant. A distinct difference in performance following
caffeine supplementation was observed between groups such that A variant homozygotes
displayed significant (p<0.05) improvement in a 40K time trial while carriers of the C
variant displayed no effect (p>0.05) (110). Therefore it is plausible the CYP1A2
polymorphism may influence individual response to caffeine supplementation and hence
influence whether or not a dose-response relationship is present. The current study
included 4 known C variants from the previous study (110). Using the same statistical
analysis as with the entire group, the data for the known C variant subjects was markedly
different from the data for the whole group. For example, although no significant
difference in 40K time was found between the 3 mg/kg dose and 6 mg/kg dose, a trend
occurred towards faster time with the 3 mg/kg dose as compared placebo (p= 0.05,
Bonferroni correction) while no trend was found between the 6 mg/kg dose and placebo
(p =0.14). In addition, although the mean 40K time was fastest among the entire group
following supplementation with the 6 mg/kg dose, the mean 40K time among the 4
known C variants was fastest following supplementation with the 3 mg/kg dose. Finally,
the 4 known C variants were removed from data analysis and the results (n=12) indicated
a stronger trend (p=0.03), toward greater improvement in time trial performance with the
6 mg/kg dose compared to the 3 mg/kg dose (as compared to the trend for the entire
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group). Additionally, without the known C variants, the 6 mg/kg dose resulted in a
significantly improved time trial performance (p=0.01) compared to the placebo whereas
the 3 mg/kg dose only resulted in a trend towards improvement compared to the placebo.
These differences found with the C variants are novel and may have contributed to our
findings of a trend (p=0.04) towards a dose-response effect between 3 mg/kg and 6
mg/kg whereby we may have had a disproportionate amount of non-C variants (A
variants homozygotes) as subjects. On the other hand, it is also possible we had
additional unknown C variants among our subjects. Therefore because C variants have
been shown to respond poorly to 6 mg/kg of caffeine in this current study as well as in
our previous study (110); the potential for a significant improvement in performance with
the 6 mg/kg dose compared to the 3 mg/kg dose may have been masked. However, we
do not know the genotype of the remaining 12 subjects; therefore we can only theorize as
to the extent, if any, of a relationship between dose-response effect and genotype.
Limitations:
As previously described, the primary mechanism for improved performance
observed with caffeine is thought to be its effect on adenosine receptors. Because
caffeine functions as an adenosine receptor antagonist throughout the central nervous
system (29,37,38,42,68,84,85,87,96) and because caffeine tolerance (as a result of
habitual caffeine use) has been shown result in an increase in adenosine receptor activity
and a decrease in β-adrenergic activity (20,47,71); prior/habitual caffeine use has been
cited as a potential reason for differences in response to caffeine. Specifically, low
caffeine users may be more sensitive to low doses of caffeine whereas habitual caffeine
users may require greater doses of caffeine to induce the same effects (40). However,
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research is equivocal regarding caffeine habituation. Van Soren et al (105) measured
cycling time to exhaustion following ingestion of 6 mg/kg caffeine after 0, 2 and 4 days
withdrawl from caffeine use as compared to the placebo. An improvement in greater
time to exhaustion (+ 6 minutes) was observed after 2 and 4 days withdrawl as compared
to 0 days withdrawl, however all 3 trials were significantly (p<0.05) better than the
placebo and none of the 3 trials significantly differed from each other. Likewise Bell et
al (6) divided 21 subjects into users (≥ 300 mg/day n=13) and non-users (< 50 mg/day) of
caffeine. Caffeine significantly (p≤ 0.05) improved cycling time to exhaustion compared
to a placebo following ingestion of 5 mg/kg caffeine taken 1, 3, or 6 hours prior to
exercise. However only the non-users demonstrated significant (p≤ 0.05) improvement
compared to the placebo following caffeine ingestion 6 hours prior to exercise.
Conversely, Wiles et al (108) reported a statistical (p<0.05) improvement in 1500 meter
run time following ingestion of 150-200 mg of caffeine compared to a placebo, but found
no association between habitual caffeine use and performance improvement. Likewise,
Tarnopolsky et al (102) reported a statistical (p<0.05) improvement in force of
contraction at 20Hz during a 2:00 tetanic stimulation of the peroneal nerve following
ingestion of 6 mg/kg caffeine compared to a placebo with no difference between caffeine
users (> 500 mg/day, n=6) and non-users (<50 mg/day, n=6). Finally, in a recent metaanalysis, Doherty and Smith (31) concluded that a period of subject withdrawl from
caffeine did not appear to have any major influence on the effects of caffeine on Rating
of Perceived Exertion (RPE).
Data from our study appeared to indicate a preferential response to the 6 mg/kg
dose, independent of previous caffeine use. Of our 4 highest and 4 lowest caffeine users,

58

7 of them performed better following ingestion of the 6 mg/kg dose as compared to the 3
mg/kg dose. Only 1 of the other dose-response studies analyzed their results in terms of
dose response and caffeine habituation, and they also did not find any apparent
relationship between optimal dose and habitual caffeine use (46). In that study, Graham
and Spriet (46) used both 3mg/kg and 6 mg/kg doses of caffeine and failed to find a
difference between either dose on treadmill time to exhaustion. Although our studies
differed in terms of mode of exercise, we did compare the same dosage amounts.
Therefore, previous research suggests our findings regarding a dose-response effect do
not appear to be influenced by our subject’s previous caffeine use.
Another potential limitation may have been the previous training of the subjects in
the week leading up to each time trial. Our data collection took place late summer and
early fall which is a popular time for cycling races and triathlons; therefore some subjects
were training for upcoming races while participating in our study. While we did not
regulate subject training in the days leading up to each trial, we did ask subjects to
maintain their normal training schedule. Although no quantitative data was obtained,
several subjects noted they used the time trials as their hard training ride for the week or
performed other modes of exercise (i.e. swimming/running) the day prior to their time
trial. In some prior studies subjects were instructed to refrain from strenuous or
exhaustive training for 24 (61) or 48 (70) hours prior to exercise. However, Desbrow et
al (28) used dosage amounts similar to the previous two studies, but did not find a doseresponse effect for improved performance despite asking their subjects to refrain from
heavy training for 24 hours prior to each trial. Likewise, Graham and Spriet (46) used
dosage amounts very similar to ours and also only asked their subjects to maintain a
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normal training schedule yet they failed to find a dose-response effect indicating
enhanced performance with a higher dose. While it is plausible that prior exercise by our
subjects may have influenced the outcome of their trials and hence the dose-response
effect; previous studies suggest otherwise. Additionally, any effect of prior exercise on
the performance of our subjects would have resulted in an increase in error variance in
our study which would have made it harder to find the resultant trend for improved
performance with 6mg/kg as compared to 3mg/kg of caffeine. Nevertheless, future doseresponse studies would be well-served to keep training logs on each subject.
Application:
Data from our study provides evidence that ergogenic effects from caffeine can be
elicited by both 3 mg/kg and 6 mg/kg of caffeine in trained cyclists performing a 40K
time trial. Our data also suggests that 6 mg/kg of caffeine may contribute to an improved
performance as compared to the 3 mg/kg dose. This finding is in contrast to what
previous literature suggests regarding a lack of dose-response improvement in
performance for dosage amounts greater than ~3mg/kg. However the results of some
studies may indicate a threshold effect with caffeine such that rate of performance
improvement decreases beyond ~6mg/kg. Thereby suggesting the optimal dosage
amount is between ~3mg/kg and ~6mg/kg. Studies comparing doses between ~3mg/kg
and 6mg/kg (or greater) are very limited, thus future studies should compare multiple
doses at amounts 3mg/kg and larger.
The mechanisms contributing to the trend toward a greater performance following
ingestion of 6 mg/kg of caffeine as compared to 3 mg/kg are unknown. However
variation in individual response to the different doses of caffeine may have been a factor,
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especially as it relates to the CYP1A2 Polymorphism. Therefore future studies should
also analyze individual, as well as group, response to multiple doses of caffeine.

61

REFERENCES
1. ANDERSON, M.E., C.R. BRUCE, S.F. FRASER, N.K. STEPTO, R. KLEIN, W.G.
HOPKINS, AND J.A. HAWLEY. Improved 2000-meter rowing performance in
competitive oarswomen after caffeine ingestion. Int. J. Sport Nutr. Exerc. Metab. 10:
464-475, 2000.
2. ANSELME, F., K. COLLOMP, B. MERCIER, S. AHMAIDI, AND C. PREFAUT.
Caffeine increases maximal anaerobic power and blood lactate concentration. Eur J.
Appl. Physiol. 65: 188-191, 1992.
3. ASTORINO, T.A., R.L. ROHMANN, AND K. FIRTH. Effect of caffeine ingestion on
one-repetition maximum muscular strength. Eur J. Appl. Physiol. 102: 127-132, 2008.
4. BECK, T.W., T.J. HOUSH, M.H. MALEK, M. MIELKE, AND R. HENDRIX. The acute
effects of a caffeine-containing supplement on bench press strength and time to running
exhaustion. J. Strength Cond. Res. 22(5): 1654-1658, 2008.
5. BELL, G.D., AND T.M. MCLELLAN. Effect of repeated caffeine ingestion on repeated
exhaustive exercise endurance. Med. Sci. Sports Exerc. 35(8): 1348-1354, 2003.
6. BELL. G.D., AND T.M. MCELLAN. Exercise endurance 1,3, and 6 h after caffeine
ingestion in caffeine users and nonusers. J. Appl. Physiol. 93: 1227-1234, 2002.
7. BELL, G.D., I. JACOBS, AND J. ZAMECNIK. Effects of caffeine, ephedrine and their
combination on time to exhaustion during high-intensity exercise. Eur. J. Appl. Physiol.
77: 427-433, 1998.
8. BERGLUND, B., AND P. HEMMINGSSON. Effects of caffeine ingestion on exercise
performance at low and high altitudes in cross-country skiers. Int. J. Sports Med. 3: 234236, 1982.
9. BIAGGIONI, I., S. PAUL, A. PUCKETT, AND C. ARZUBIAGA. Caffeine and
theophylline as adenosine receptor antagonists in humans. J. Pharmacol Exp. Ther. 258:
588-593, 1991.
10. BIGLAND-RITCHIE, B., D.A. JONES, AND J.J. WOODS. Excitation frequency and
muscle fatigue: electrical responses during human voluntary and stimulated contractions.
Exp. Neurol. 64; 414-427, 1979.
11. BLOCK, B.M., S.R. BARRY, AND J.A. FAULKNER. Aminophylline increases
submaximal power but not intrinsic velocity of shortening of frog muscle. J. Appl.
Physiol. 73: 71-74, 1992.
12. BRIDGE, C.A., AND M.A. JONES. The effect of caffeine ingestion on 8km run
performance in a field setting. J. Sports Sci. 24(4): 433-439, 2006.

62

13. BRUCE, C.R., M.E. ANDERSON, S.F. FRASER, N.K. STEPTO, R. KLEIN, W.G.
HOPKINS, AND J.A. HAWLEY. Enhancement of 2000-m rowing performance after
caffeine ingestion. Med. Sci. Sports Exerc. 32: 1958-1963, 2000.
14. BURKE, L. Caffeine and sports performance. Appl. Physiol. Nutr. Metab. 33: 1319-1334,
2008.
15. CADARETTE, B.S., L. LEVINE, C.L. BERUBE, B.M. POSNER, AND W.J. EVANS.
Effects of varied dosages of caffeine on endurance exercise to fatigue. In: Biochemistry
of Exercise 13th ed. H.G. Knuttgen, J.A. Vogel, and J. Poortmans, ed. Champaign, IL:
Human Kinetics, 1982. Pp. 871-876.
16. CLAUSEN, T. Na+-K+ pump regulation and skeletal muscle contractility. Physiol. Rev.
83: 1269-1324, 2003.
17. COLLOMP, K., S. AHMAIDI, J.C. CHATARD, M. AUDRAN, AND C. PREFAUT.
Benefits of caffeine ingestion on sprint performance in trained and untrained swimmers.
Eur. J. Appl. Physiol. Occup. Phsysiol. 64: 377-380, 1992.
18. CONWAY, K.J., R. ORR, AND S. R. STANNARD. Effect of a divided caffeine dose on
endurance cycling performance, postexercise urinary caffeine concentration, and plasma
paraxanthine. J. Appl. Physiol. 94: 1557-1562, 2003.
19. CORNELIS, M.C., A. EL-SOHEMY, E.K. KABAGAMBE, AND H. CAMPOS. Coffee,
CYP1A2 genotype, and risk of myocardial infarction. JAMA 295(10): 1135-1141, 2006.
20. CORTI, R. C. BINGGELI, I. SUDANO, L. SPIEKER, E. HANSELER, F.
RUSCHITZKA, W.F. CHAPLIN, T.F. LUSCHER, AND G. NOLL. Coffee acutely
increases sympathetic nerve activity and blood pressure independently of caffeine
content: role of habitual versus non-habitual drinking. Circulation. 106:2935-2940, 2002.
21. COSTILL, D. L, G.P.DALSKY, AND W.J. FINK. Effects of caffeine ingestion on
metabolism and exercise performance. Med. Sci. sports Exerc. 10:155-158, 1978.
22. COX, R.R., B. DESBROW, P.G. MONTGOMERY, M.E. ANDERSON, C.R. BRUCE,
T.A. MACRIDES, D.T. MARTIN, A. MOQUIN, A. ROBERTS. J.A. HAWLEY, AND
L.M. BURKE. Effect of different protocols of caffeine intake on metabolism and
endurance performance. J. Appl. Physiol. 93: 990-999, 2002.
23. COYLE, E.F. Ergogenic aids. Clin Sports Med 3: 731-742, 1984.
24. DAVIS, J.M., Z. ZHAO, H.S. STOCK, K.A. MEHL, J. BUGGY, AND G.A. HAND.
Central nervous system effects of caffeine and adenosine on fatigue. Am J. Physiol.
Regul. Integr. Comp. Physiol. 284: R399-R404, 2003.

63

25. DELAY, M., B. RIBALET, AND J. VERGARA. Caffeine potentiation of calcium
release in frog skeletal muscle fibres. J. Physiol. 375: 535-559, 1986.
26. DEL COSO, J., E. ESTEVEZ, AND R. MORA-RODRIGUEZ. Caffeine effects on shortterm performance during prolonged exercise in the heat. Med. Sci. Sports Exerc. 40 (4):
744-751, 2008.
27. DENADAI, B.S., AND M.L.D.R. DENADAI. Effects of caffeine on time to exhaustion
in exercise performed below and above the anaerobic threshold. Braz. J. Med. Bio. Res.
31: 581-585, 1998.
28. DESBROW, B., C.M. BARRETT, C.L. MINAHAN, G.D. GRANT, AND M.D.
LEVERITT. Caffeine, cycling performance, and exogenous CHO oxidation: a doseresponse study. Med. Sci. Sports Exerc. 41 (9): 1744-1751, 2009.
29. DEWS, P.B., C.P. O’BRIEN, AND J. BERGMAN. Caffeine: behavioral effects of
withdrawl and related issues. Food Chem. Toxicol. 40: 1257-1261, 2002
30. DIXON, A.K., A.K. GUBITZ, D.J.S. SIRINATHSINGHJI, P.J. RICHARDSON, AND
T.C. FREEMAN. Tissue distribution of adenosine receptor for mRNAs in the rat. Br. J.
Pharmacol. 118: 1461-1468, 1996.
31. DOHERTY, M., AND P.M. SMITH. Effects of caffeine ingestion on rating of perceived
exertion during and after exercise: a meta-analysis. Scand. J. Sci. Sports 15: 69-78, 2005.
32. DOHERTY, M., P.M. SMITH, M.G. HUGHES, AND R.C. DAVISON. Caffeine lowers
perceptual response and increases power output during high-intensity cycling. J. Sports
Sci. 22: 637-643, 2004.
33. DUNWIDDIE, T.V., AND S.A. MASINO. The role and regulation of adenosine in the
central nervous system. Annu. Rev. Neurosci. 24: 31-55, 2001.
34. EDWARDS, R.H.T., D.K. HILL, D.A. JONES, AND P.A. MERTON. Fatigue of long
duration in human skeletal muscle after exercise. J. Physiol. 264: 865-879, 1977.
35. ENGELS, H.J. J.C. WIRTH, S. CELIK, AND J.L. DORSEY. Influence of caffeine on
metabolic and cardiovascular functions during sustained light intensity cycling and at
rest. Int. J. Sports Nutr. 9: 361-370, 1999.
36. ESSIG, D., D.L. COSTILL, AND P.J. VAN HANDEL. Effects of caffeine ingestion on
utilization of muscle glycogen and lipid during leg ergometer cycling. Int. J. Sports Med.
1: 86-90, 1980.
37. FISONE, G., A., A. BORGKVIST, AND A. USIELLO. Caffeine as a psychomotor
stimulant: mechanism of action. Cell Mol. Life Sci. 61: 857-872, 2004.

64

38. FREDHOLM, B.B., K. BATTIG, H. HOLMEN, A. NEHLIG, AND E.E. ZVARTAU.
Actions of caffeine in the brain with special reference to factors that contribute to its
widespread use. Pharmacol. Rev. 51: 83-133, 1999.
39. FRYER, M.W., AND I.R. NEERING. Actions of caffeine on fast and slow twitch
muscles of the rat. J. Physiol. 416: 435-454, 1989.
40. GANIO, M.S., J.F. KLAU, D.J. CASA, L.W. ARMSTRONG, AND C.M. MARESH.
Effect of caffeine on sport-specific endurance performance: A systematic review. J.
Strength Cond. Res. 23(1): 315-324, 2009.
41. GLAISTER, M., G. HOWATSON, C.S. ABRAHAM, R. A. LOCKEY, J.E. GOODWIN,
P. FOLEY, AND G. MCINNES. Caffeine supplementation and multiple sprint running
performance. Med. Sci. Sports. Exerc. 40 (10): 1835-1840, 2008.
42. GRAHAM, T.E. Caffeine and exercise: metabolism, endurance and performance. Sports
Med. 31: 785-807, 2001.
43. GRAHAM, T.E., E. HIBBERT, AND P. SATHASIVAM. Metabolic and exercise
endurance effects of coffee and caffeine ingestion. J. Appl. Physiol. 85: 883-889, 1998
44. GRAHAM, T.E., J.W.E. RUSH, AND M.H. SOEREN. Caffeine and exercise:
metabolism and performance. Can. J. Appl. Physiol. 19: 111-138, 1994.
45. GRAHAM, T.E., AND L. L. SPRIET. Performance and metabolic responses to a high
caffeine dose during prolonged exercise. J. Appl. Physiol. 71: 2292-2298, 1991.
46. GRAHAM, T.E., AND L.L. SPRIET. Metabolic, catecholamine, and exercise
performance responses to various does of caffeine. J. Appl. Physiol. 78: 867-874, 1995.
47. GREDEN, J.F. Anxiety or caffeinism: a diagnostic dilemma. Am. J. Psychiatry 131:
1089-1092, 1974.
48. GREEN, J.M., P.J. WICKWIRE, J.R. MCLESTER, S. GENDLE, G. HUDSON, R.C.
PRITCHETT, AND C.M. LAURENT. Effects of caffeine in repetitions to failure and
rating of perceived exertion during resistance training. Int. J. Sport Physiol. Perf. 2: 250259, 2007.
49. GREER, F., D. FRIARS, AND T.E. GRAHAM. Comparison of caffeine and
theophylline ingestion: exercise metabolism and endurance. J. Appl. Physiol. 89: 18371844, 2000.
50. GREER, F., J. MORALES, AND M. COLES. Wingate performance and surface EMG
frequency variables are not affected by caffeine ingestion. Appl. Physiol. Nutr. Metab.
31: 597-603, 2006.

65

51. GROSSO, L.M., AND M.B. BRACKEN. Caffeine metabolism, genetics, and perinatal
outcomes: a review of exposure assessment considerations during pregnancy. Ann.
Epidemiol 15: 46-466, 2005.
52. GU, L., F.J. GONZALEZ, W. KALOW, AND B.K. TANG. Biotransformation of
caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human
CYP1A@ and CYPE1. Pharmacogenetics. 2: 73-77, 1992.
53. HAN, X.M., D.S. OU-YANG, P.X. LU, C.H. JIANG, Y. SHU, X.P. CHEN, Z.R. TAN,
AND H.H. ZHOU. Plasma caffeine metabolite ratio (17X/137X) in vivo associated with
G-2964A and C734A polymorphisms of human CYP1A2. Pharmacogenetics 11(5): 429435, 2001.
54. HERRMANN-FRANK, A., H.C. LUTTGAU, AND D.G. STEPHENSON. Caffeine and
excitation-contraction coupling in skeletal muscle: a stimulating story. J. Muscle Res.
Cell. Motil. 20: 223-237, 1999.
55. HOGERVORST, E., S. BANDELOW, J. SCHMITT, R. JENTJENS, M. OLIVERIA, J.
ALLGROVE, T. CARTER, AND M. GLEESON. Caffeine improves physical and
cognitive performance during exhaustive exercise. Med. Sci. Sports Exerc. 40(10): 18411851, 2008.
56. HUDSON, G.M., J.M. GREEN, P.A. BISHOP, AND M.T. RICHARDSON. Effects of
caffeine and aspirin on light resistance training performance, perceived exertion, and pain
perception. J. Strength Cond. Res 22(6): 1950-1957, 2008.
57. HULSTON, C.J., AND A.E. JEUKENDRUP. Substrate metabolism and exercise
performance with caffeine and carbohydrate intake. Med. Sci. Sports Exerc. 40(12):
2096-2104, 2008.
58. IVY, J.L., D.L. COSTILL, W.J. FINK, AND R.W. LOWER. Influence of caffeine and
carbohydrate feeding on endurance performance. Med. Sci. Sports 11: 6-11, 1979.
59. JACKMAN, M., P. WENDLING, D. FRIARS, AND T.E. GRAHAM. Metabolic,
catecholamine, and endurance responses to caffeine during intense exercise. J. Appl.
Physiol. 81(4): 1658-1663, 1996.
60. JACOBSON, T.L., M.A. FEBBRAIO, M.J. ARKINSTALL, AND J. A. HAWLEY.
Effect of caffeine co-ingested with carbohydrate or fat on metabolism and performance in
endurance-trained men. Exp. Physiol. 86(1): 137-144, 2001.
61. JENKINS, N.T., J.L. TRILK, A. SINGHAL, P.J. O’CONNOR, AND K.J. CURETON.
Ergogenic effects of low doses of caffeine on cycling performance. Int. J. Sport Nutr.
Exerc. Metab. 18: 328-342, 2008.

66

62. JEUKENDRUP, A.E., W.M.H. SARIS, F. BROUNS, AND A.D.M. KESTER. A new
validated endurance performance test. Med. Sci. Sports Exerc. 28: 266-270, 1996.
63. JUDELSON, D.A., L.E. ARMSTRONG, B. SOKMEN, M.W. ROTI, D.J. CASA, AND
M.D. KELLOGG. Effect of chronic caffeine intake on choice reaction time, mood, and
visual vigilance. Physiol Behav 85: 629-634, 2005.
64. KALMAR, J.M., AND E. CAFARELLI. Caffeine: a valuable tool to study central fatigue
in humans? Exerc. Sport Sci. Rev. 32: 143-147, 2004.
65. KALMAR, J.M., AND E. CAFARELLI. Effects of caffeine on neuromuscular function.
J. Appl. Phsyiol. 87: 801-808, 1999.
66. KANG, H., H. KIM, AND B. KIM. Acute effects of caffeine intake on maximal
anaerobic power during the 30s Wingate cycling test. J. Exerc. Physiol. Online. 1, 1998.
67. KALOW, W., AND B.K. TANG. Use of caffeine metabolite ratios to explore CYP1A2
and xanthine oxidase activities. Clin Pharmacol Ther. 50: 508-519, 1991.
68. KEISLER, B.D. AND T.D. ARMSEY 2ND. Caffeine as an ergogenic aid. Curr. Spors
Med. Rep. 5:215-219, 2006.
69. KOLBECK, R.C., AND W.A. SPIER. Theophylline, fatigue, and diaphragm
contractility: cellular levels of 45Ca and cAMP. J. Appl. Physiol. 70: 1933-1937, 1991.
70. KOVACS, E.M.R., J.H.C.H. STEGEN, AND F. BROUNS. Effect of caffeinated drinks
on substrate metabolism, caffeine excretion, and performance. J. Appl. Physiol. 85(2):
709-715, 1998.
71. LANE, J.D., AND B.G. PHILIPS-BUTE. Caffeine deprivation affects vigilance
performance and mood. Phys. Behav. 65: 171-175, 1998
72. LIN, Y., AND J.W. PHILLIS. Characterization of the depression of rat cerebral cortical
neurons by selective adenosine agonists. Brain Res. 540: 3307-310, 1991.
73. LOPES, J.M., A.J. JARDIM, J.V. ARANDA, AND P.T. MACKLEM. Effect of caffeine
on skeletal muscle function before and after fatigue. J. Appl. Physiol. 54: 1303-1305,
1983.
74. MACINTOSH, B.R., AND B.M .WRIGHT. Caffeine ingestion and performance of a
1,500-metre swim. Can J. Appl. Physiol. 20: 168-177, 1995.
75. MCNAUGHTON, L.R., R.J. LOVELL, J. SIEGLER, A. W. MIDGLEY, L. MOORE,
AND D.J. BENTLEY. The effects of caffeine ingestion on time trial cycling
performance. Int. J. Sports Physiol. Perform. 3: 157-163, 2008.

67

76. MEYERS, B.M., AND E. CAFARELLI. Caffeine increases time to fatigue by maintain
force and not by altering firing rates during submaximal isometric contractions. J. Appl.
Physiol. 99: 1056-1063, 2005.
77. MOTL, R.W., P.J. O’CONNOR, AND R.K. DISHMAN. Effect of caffeine on
perceptions of leg muscle pain during moderate intensity cycling exercise. J. Pain. 4:
316-321, 2003
78. MYERS, D.E. Z. SHAIKH, AND T.G. ZULLO. Hypoalgesic effect of caffeine in
experimental ischemic muscle contraction pain. Headache. 37: 654-658, 1997
79. NAKAJIMA, M., T. YOKOI, M. MIZUTANI, M. KINOSHITA, M. FUNAYAMA,
AND T. KAMATAKI. Genetic polymorphism in the 5’-flanking region of human
CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J. Biochem. 125: 803-808,
1999.
80. NEHLIG, A., J.L. DAVAL, AND G. DEBRY. Caffeine and the central nervous system:
mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res.
Rev. 17: 139-170, 1992.
81. O’CONNOR, P.J., R.W. MOTL, S.P. BROGLIO, AND M.R. ELY. Dose-dependent
effect of caffeine on reducing leg muscle pain during cycling exercise is unrelated to
systolic blood pressure. Pain. 109: 291-298, 2004.
82. O’ROURKE, M.P., B.J. O’BRIEN, W.L. KNEZ, AND C.D. PATON. Caffeine has a
small effect on 5-km running performance of well-trained and recreational runners. J. Sci.
Med. Sport. 11: 231-233, 2008.
83. PALMER, G.S., S.C. DENNIS, T.D. NOAKES, AND J.A. HAWLEY. Assessment of the
reproducibility of performance testing on an air-braked cycler ergometer. Int. J. Sports
Med. 17 (4): 293-298, 1996.
84. PALUSKA, S.A. Caffeine and exercise. Curr. Sports Med. Rep. 2: 213-219, 2003.
85. PARSONS, W.D., AND A.H. NEIMS. Effect of smoking on caffeine clearance. Clin
Pharmacol Ther. 24: 40-45, 1978.
86. PASMAN, W.J., M.A. VAN BAAK, A.E. JEUKENDRUP, AND A. DEHAAN. The
effect of different dosages of caffeine on endurance performance time. Int. J. Sports Med.
16: 225-230, 1995.
87. PHILLIS, J.W., J.P. EDSTROM, G.K. KOSTOPOULOS, AND J.R. KIRKPATRICK.
Effects of adenosine and adenine nucleotides on synaptic transmission in the cerebral
cortex. Can J. Physiol. Pharmacol. 57: 1289-1312, 1979.

68

88. PENNER, R. E. NEHER, H. TAKESHIMA, S. NISHIMURA, AND S. NUMA.
Functional expression of the calcium release channel from skeletal muscle ryanodine
receptor cDNA. FEBS Lett. 259: 217-221, 1989.
89. RASMUSSEN, B.B., T.H. BRIX, K.O. KYVIK, AND K. BROSEN. The interindividual
differences in the 3-demethylation of caffeine alias CYP1A2 is determined by both
genetic and environmental factors. Pharmacogenetics. 12: 473-478, 2002.
90. REKLING, J.C., G.D. FUNK, D.A. BAYLISS, X.W. DONG, AND J.L. FELDMAN.
Synapitc control of motoneuronal excitability. Physiol Rev. 80: 767-852, 2000.
91. REPPERT, S.M., D.R. WEAVER, J.H. STEHLE, AND S.A. RIVKEES. Molecular
cloning and characterization of a rat A1-adenosine receptor that is widely expressed in
brain and spinal cord. Mol. Endocrinol. 5: 1037-1048, 1991.
92. ROY, B.D., M.J. BOSMAN, AND M.A. TARNOPOLSKY. An acute oral dose of
caffeine does not alter glucose kinetics during prolonged dynamic exercise in trained
endurance athletes. Eur J Appl. Physiol. 85: 280-286, 2001.
93. SACHSE, C., J. BROCKMOLLER, S. BAUER, AND I. ROOTS. Functional
significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene
tested with caffeine. Br. J. Clin. Pharmacol. 47(4): 445-449, 1999.
94. SAWYNOK, J. Adenosine receptor activation and nociception. Eur. J. Pharmacol. 317:
1-11, 1998.
95. SCHNEIKER, K.T., D. BISHOP, B. DAWSON, AND L.P. HACKETT. Effects of
caffeine on prolonged intermit-sprint ability in team-sport athletes. Med. Sci. Sports
Exerc. 38: 578-585, 2006.
96. SMITS, P., P. BOEKEMA, R. DEABREU, T. THEIN, AND A. VANTLAAR. Evidence
for an antagonism between caffeine and adenosine in the human cardiovascular system. J.
Cardiovasc. Pharmacol. 10: 136-143, 1987.
97. SPRIET, L.L. Caffeine. In: Performance-Enhancing Substances in Sport and Exercise.
M.S. Bahrke and C.E. Yesalis, ed. New York: Human Kinetics, 2002. Pp. 267-278
98. SPRIET, L.L. AND R.A. HOWLETT. Caffeine. In: Nutrition in Sport. R.J. Maughan ,ed.
Oxford: Blackwell Scientific, 2000. Pp. 379-392
99. SPRIET, L.L., D.A. MACLEAN, D.J. DYCK, E. HULTMAN, G. CEDERBLAD, AND
T.E. GRAHAM. Caffeine ingestion and muscle metabolism during prolonged exercise in
humans. Am. J. Physiol. 262(25) E891-E898, 1992.

69

100. SUNGPIL, R., C. SUNG-KEUN, J. SEUNG-SAM, S.HEAJUNG, C. YOUN-SOO,
SOOCHUN, AND L. KIWON. Caffeine as a lipolytic food component increases
endurance performance in rats and athletes. J. Nutr. Sci. Vitaminol. 47: 139-146, 2001.
101. SUPINSKI, E.C. G.S. DEAL JR. AND S.G. KELSON. Caffeine effect on respiratory
muscle endurance and sense of effort during loaded breathing. J. Appl. Physiol. 60: 20402047, 1986.
102. TARNOPOLSKY, M., AND C. CUPIDO. Caffeine potentiates low frequency skeletal
muscle force in habitual and nonhabitual caffeine consumers. J. Appl. Physiol. 89: 17191724, 2000.
103. TARNOPOLSKY, M.A., S.A. ATKINSON, J. D. MACDOUGALL, D.G. SALE, AND
J.R. SUTTON. Physiological responses to caffeine during endurance running in habitual
caffeine users. Med. Sci. Sports Exerc. 21(4): 418-424, 1989.
104. TRICE, I., AND E.M. HAYMES. Effects of caffeine ingestion on exercise-induced
changes during high-intensity, intermittent exercise. Int. J. Sport Nutr. 5: 37-44, 1995.
105. VAN SOEREN, M.H., AND T.E. GRAHAM. Effect of caffeine on metabolism, exercise
endurance, and catecholamine response after withdrawl. J. Appl. Physiol. 85(4): 14931501, 1998.
106. VAN SOEREN, M.H., P. SATHASIVAM, L.L. SPRIET, AND T.E .GRAHAM.
Caffeine metabolism and epinephrine responses during exercise in users and nonusers. J.
Appl. Physiol. 75: 805-812, 1993.
107. WALKER, G.J., A. DZIBUAK, L. HOUGHTON, C. PRENDERGAST, L. LIM, AND
N.C. BISHOP. The effect of caffeine ingestion on human neutrophil oxidative burst
responses following time-trial cycling. J. Sports Sci. 26(6): 611-619, 2008.
108. WILES, J.D., S.R. BIRD, J. HOPKINS, AND M. RILEY. Effect of caffeinated coffee on
running speed, respiratory factors, blood lactate and perceived exertion during 1500-m
treadmill running. Br. J. Sports Med. 26(2): 116-120, 1992.
109. WILLIAMS, J.H., J.F. SIGNORILE, W.S., BARNES, AND T.W. HENRICH. Caffeine,
maximal power output and fatigue. Br. J. Sports Med. 22: 132-134, 1988.
110. WOMACK, C.J., M.J. SAUNDERS, M.K. BECHTEL, D.J. BOLTON, B.A.
HOLROYD, M. GARVEY, W. DUNHAM, M. HANCOCK, AND L.B. MATTOX. The
influence of a CYP1A2 polymorphism on the ergogenic effects of caffeine. Unpublished
Research. James Madison University Human Performance Laboratory, 2007.
111. YEO, S.E., R.L.P.G. JENTJENS, G.A. WALLIS, AND A.E. JEUKENDRUP. Caffeine
increases exogenous carbohydrate oxidation during exercise. J. Appl. Physiol. 99: 844850, 2005.

70

